Podcasts about bnt162b2 mrna covid

In his weekly clinical update, Dr. Griffin briefly discusses the E.coli outbreak associated with onions from McDonald's before deep diving into the announcement of Robert F Kennedy Jr. nomination for Secretary of Human and Health Services with highlights from MicrobeTV's own Vincent Racaniello and Paul Offit (Beyond the Noise), the global measles outbreak, underutilization of influenza antivirals for children and teens, the $350 million 2025 order for mpox vaccination, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, the effectiveness of N95 mask, the interplay between transmission and immunity for virus spread, where to find PEMGARDA, and translational science being conducted to understand long COVID including ongoing clinical trials, development of animal models and how sex may affect outcomes. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Micky D's onions linked to E. coli outbreak….another reason to not eat fast food (CDC) RFK Jr. series…..does he get anything right? (FactCheck.org) Salk polio vaccine : a calculated risk? (BMJ) How to conduct a controlled vaccine trial (American Journal Public Health Nations Health) Safety and efficacy of BNT162b2 mRNA COVID-19 vaccine (NEJM) Another Safety and efficacy study: mRNA-1273 SARS-CoV-2 vaccine (NEJM) …..SERIOUSLY! can't RFK Jr get it correct? (FactCheck.org) ‘I've Come Home Today': RFK Jr. (the Defenders Children's Health Defense News & Views) Thank God for sensible people: Racaniello and Offit (microbeTV) RFK Jr. : MAN CAN'T YOU GET ANYTHING RIGHT? (Annenberg Public Policy Center: University of Pennsylvania) No harm in repeating Vinny! Thank God for sensible people: Racaniello and Offit (microbeTV) Did America think Trump-Kennedy through? …..really did you think this through? (microbeTV) Make American Healthy Again? ……I will have fries with that….SUPERSIZED! (Wall Street Journal) Keep the United States HEALTHY! (Safe Communities Coalition) Measles in the US (CDC Measles: Rubeola) The merry-go-around of measles (JID) It is a measles outbreak! (CDC Measles: Rubeola) 10.3 million measles infections in 2023….but no vaccine (WHO) Underutilization of influenza antiviral treatment among children and adolescents (CDC MMWR) Increase in influenza infection in children…..(CIDRAP) Influenza weekly surveillance report: clift notes (CDC FluView) $340 million doses of mpox vaccine ordered for 2025 (Reuters) Mpox in NYC (JID) Respiratory virus activity (CDC Respiratory Illnesses) COVID-19 deaths (CDC) COVID-19 national and regional trends (CDC) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) N95 Filtering Facepiece Respirator use (JAMA Open Network) The Risk of SARS-CoV-2 Transmission in Community Indoor Settings (JID) Lower levels of household transmission of SARS-CoV-2 VOC Omicron compared to Wild-type: an interplay between transmissibility and immune status (JID) Enhanced placental antibody transfer efficiency with longer interval between maternal RSV vaccination and birth (AJOG: American Journal of Obstetrics and Gynecology) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Fusion center near you….if in NY (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Infectious Disease Society guidelines for treatment and management (ID Society) Perceptions and Barriers to Outpatient Antiviral Therapy for COVID-19 and Influenza as Observed by Infectious Disease Specialists (OFID) Drug–Drug Interactions with Nirmatrelvir/Ritonavir(Infectious Diseases and Therapy) Drug interaction checker (University of Liverpool) Real-world effectiveness of nirmatrelvir-ritonavir and molnupiravir  (CMI: Clinical Microbiology and Infection) Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (CID) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC) Managing healthcare staffing shortages (CDC) Steroids, dexamethasone at the right time (OFID) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long-COVID Clinical Trials (RECOVER) Initiating Long Covid RECOVERy (Science Translational Medicine) Beyond acute SARS-CoV-2 infection in children (Science Translational Medicine) Long COVID and Osler's Web: Chronic Fatigue Syndrome (goodreads) Sex differences in post infection sequalae  (Science Translational Medicine) Symptoms after Lyme disease: What's past is prologue (Science Translational Medicine) Animal models of Long COVID (Science Translational Medicine) Therapies for Long COVID (Science Translational Medicine) Sex differences and immune correlates of Long Covid development, symptom persistence, and resolution (Science Translational Medicine) The Long COVID ISSUE (Science Translational Medicine) Letters read on TWiV 1168 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

Continuing the powerful conversation with Dr. Eric Payne, this second part dives even further into the challenges facing healthcare professionals in the wake of the COVID pandemic. Dr. Payne sheds light on the rising fear among physicians who hesitate to speak out against mainstream medical narratives due to censorship and professional repercussions. We examine the growing concerns about vaccine safety, particularly in relation to neurological injuries, and highlight cases of doctors facing backlash for raising these issues. The episode also speaks to the profound effects of masking mandates on children's development and emphasizes the urgent need for critical thinking and open dialogue in both the medical community and society. Tune in for this thought-provoking discussion that encourages us all to engage in truth-seeking discussions that build a better future. Dr. Eric Payne is a neurologist and clinical researcher specializing in pediatric neurology, epilepsy, neuroinflammation, and neurocritical care. He previously worked as an epileptologist and pediatric neurologist at Mayo Clinic (2014-2020) and at Alberta Children's Hospital (2020-2023).  He completed medical school and residency at the University of Calgary, and fellowship training in pediatric neurocritical care and epilepsy at the Hospital for Sick Children in Toronto. He obtained a Master of Public Health from Harvard University and is board certified in Neurology (FRCPC) and Clinical Electroencephalography (CSCN).  —Listen to Part One: Reclaiming Integrity in Medicine with Top Pediatric Neurologist Dr. Eric Payne: https://markgroves.com/episode/reclaiming-integrity-in-medicine-with-top-neurologist-dr-eric-payne/  References from the Episode: —Dr. Eric Payne's Letter: https://smartcdn.gprod.postmedia.digital/calgaryherald/wp-content/uploads/2021/09/Sep-15-FINAL-PAYNE-CPSA-letter.pdf  —Full List of Dr. Payne's References From His Letter:  https://static.showit.co/file/rXKal_TV4PXpWv42QajRqA/237093/sep-15-final-payne-cpsa-letter-references.pdf  —Still Face Experiment: Dr. Edward Tronick: https://youtu.be/vmE3NfB_HhE?si=QivHWP9_jREexK3s&t=34 —Cochrane Report on Face Masks: https://www.cochrane.org/CD006207/ARI_do-physical-measures-such-hand-washing-or-wearing-masks-stop-or-slow-down-spread-respiratory-viruses  —Updated Definitions of Immunity and Vaccine: https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm  —Primary Trials: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine: https://www.nejm.org/doi/full/10.1056/NEJMoa2034577  Resources: —Ready to transform your relationships? Download The Relationship Toolkit for free and learn the 5 essential skills to thrive in love and life! https://go.markgroves.com/relationship-toolkit-podcast  If you want to dive deeper into Mark's content, search through every episode, find specific topics we've covered, and ask him questions, go to his Dexa page: https://dexa.ai/markgroves Themes: COVID-19 pandemic response, Public Health Measures Critique, Dr. Eric Payne Interview, Dr. Eric Payne Letter, Mental Health During Pandemic, School Closures and Children, Vaccine Injuries and Recovery, Media and Public Health Narratives, Societal Impact of COVID-19, Emotional Healing Post-Pandemic, Pediatric Neurologist, Vaccine Safety Concerns, Censorship in Healthcare, Masking and Child Development, Critical Thinking in Medicine, Truth in Healthcare, Healthcare System Accountability, Open Dialogue in Medicine, Medical Censorship Contact us at podcast@markgroves.com for sponsor product support, questions, comments, or just to say hello! Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Eric Payne, an esteemed pediatric neurologist with a background in public health, offers an insightful and thought-provoking critique of the public health responses to COVID-19. In this part one of a two-part conversation, he discusses how fear, media narratives, and public health policies have deeply impacted society, particularly children. Dr. Payne explores the unintended consequences of lockdowns, school closures, and mask mandates, highlighting the emotional, social, and ethical dilemmas they created. His reflections challenge mainstream perspectives, advocating for more open dialogue around these interventions, especially in the face of widespread public mistrust. This conversation invites us all to reconsider the long-term impacts of pandemic policies and opens up space for healing and understanding across diverse viewpoints. Dr. Eric Payne is a neurologist and clinical researcher specializing in pediatric neurology, epilepsy, neuroinflammation, and neurocritical care. He previously worked as an epileptologist and pediatric neurologist at Mayo Clinic (2014-2020) and at Alberta Children's Hospital (2020-2023).  He completed medical school and residency at the University of Calgary, and fellowship training in pediatric neurocritical care and epilepsy at the Hospital for Sick Children in Toronto. He obtained a Master of Public Health from Harvard University and is board certified in Neurology (FRCPC) and Clinical Electroencephalography (CSCN).  References from the Episode: —Dr. Eric Payne's Letter: https://smartcdn.gprod.postmedia.digital/calgaryherald/wp-content/uploads/2021/09/Sep-15-FINAL-PAYNE-CPSA-letter.pdf  —TikTok Tics: https://pmc.ncbi.nlm.nih.gov/articles/PMC8564823/  —Updated Definitions of Immunity and Vaccine: https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm  —Full List of Dr. Payne's References From His Letter:  https://static.showit.co/file/rXKal_TV4PXpWv42QajRqA/237093/sep-15-final-payne-cpsa-letter-references.pdf  —Cochrane Report on Face Masks: https://www.cochrane.org/CD006207/ARI_do-physical-measures-such-hand-washing-or-wearing-masks-stop-or-slow-down-spread-respiratory-viruses  —Primary Trials: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine: https://www.nejm.org/doi/full/10.1056/NEJMoa2034577  Resources: —Ready to transform your relationships? Download The Relationship Toolkit for free and learn the 5 essential skills to thrive in love and life! https://go.markgroves.com/relationship-toolkit-podcast  If you want to dive deeper into Mark's content, search through every episode, find specific topics we've covered, and ask him questions, go to his Dexa page: https://dexa.ai/markgroves Themes: COVID-19 pandemic response, Public Health Measures Critique, Dr. Eric Payne Interview, Dr. Eric Payne Letter, Mental Health During Pandemic, School Closures and Children, Vaccine Injuries and Recovery, Media and Public Health Narratives, Societal Impact of COVID-19, Emotional Healing Post-Pandemic This episode is sponsored by Cozy Earth: Use code GROVES for 40% off sitewide at http://www.cozyearth.com Contact us at podcast@markgroves.com for sponsor product support, questions, comments, or just to say hello! Learn more about your ad choices. Visit megaphone.fm/adchoices

In Part two of this two-part story, Dr. Francis Collins, former head of the National Institutes of Health during COVID, and Travis Tripodi, a strong conservative critic of the US COVID response Dr. Collins helped shape, attempt the impossible —  sparring on everything from vaccine mandates to natural immunity freely, fully, and without losing it.  What does their collision achieve? And what does it leave hanging? April Lawson joins Mónica to break down this extraordinary conversation and figure out what it takes for the rest of us to tackle the hardest political disagreements we face… without getting burned.      Study: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (December 31, 2020)  Study: Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections (August 25, 2021) Rachel Maddow Vaccination Segment (April 9, 2021) Additional Background: Derate the Hate Interview with Dr. Francis Collins Additional Background: Derate the Hate Interview with Travis Tripodi NIH: Vaccine Q&A with Dr Francis Collins (May 7, 2021) Braver Angels Debates: Learn more and register here: https://braverangels.org/what-we-do/debates/  Submit a question: If you've found yourself mulling on a concern or reflection as you've listened, turn it into a question and share it with us in a quick email to abraverway@braverangels.org. Mónica and friends will be answering questions on an upcoming episode.  Subscribe: If you like what you've heard, hit subscribe, and leave us a 5 star review!  Share this episode: https://braverangels.org/a-braver-way-episode-8/  Follow us: Instagram | X/ twitter | TikTok | Youtube See omnystudio.com/listener for privacy information.

Find Monica:  Website: https://monicasdeepdives.com Twitter: https://twitter.com/monicaperezshow Rokfin: https://rokfin.com/deepdives Rumble: https://rumble.com/user/monicaperezshow YouTube: https://www.youtube.com/c/MonicaPerez  Shownotes: 1) EMA Quality Report - Rapporteurs-Rolling-Review-Report-Quality-COVID-19-mRNA-Vaccine- BioNTec.doc (live.com) 2) SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination: https://onlinelibrary.wiley.com/doi/10.1111/apm.13294 3) Biodistribution of mRNA COVID-19 vaccines in human breast milk https://www.thelancet.com/action/showPdf?pii=S2352-3964%2823%2900366-3 4) FDA - Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum https://www.fda.gov/media/144416/download 5) EMA Comirnaty Assessment Report - https://www.ema.europa.eu/en/documents/assessment- report/comirnaty-epar-public-assessment-report_en.pdf 6) Three decades of messenger RNA vaccine development - ScienceDirect 7) Frontiers | Are There Hidden Genes in DNA/RNA Vaccines? (frontiersin.org) 8) Effect of mRNA Vaccine Manufacturing Processes on Efficacy and Safety Still an Open Question | The BMJ 9) Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line (nih.gov) 10) dsDNA variance in Pfizer Docs - by Anandamide (substack.com) 11) COVID-19 primary series and booster vaccination and immune imprinting https://www.medrxiv.org/content/10.1101/2022.10.31.22281756v1.full.pdf 12) Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061025 13) A SYSTEMATIC REVIEW OF AUTOPSY FINDINGS IN DEATHS AFTER COVID-19 VACCINATION: https://zenodo.org/record/8120771 14) Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine (Cleveland Clinic Study): https://academic.oup.com/ofid/article/10/6/ofad209/7131292?login=false 15) Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents: https://pubmed.ncbi.nlm.nih.gov/36006288/ 16) Deep sequencing of the Moderna and Pfizer bivalent vaccines identifies contamination of expression vectors designed for plasmid amplification in bacteria | Kevin McKernan: https://rumble.com/v2c785k-march-8-2023.html?mref=umbzp&mc=dprv6 17) BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis: https://onlinelibrary.wiley.com/doi/10.1111/eci.13759 18) SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents: https://jamanetwork.com/journals/jamacardiology/fullarticle/2791253 19) Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults: https://www.sciencedirect.com/science/article/pii/S0264410X22010283 20) N1 methylpseudouridine is incorporated with higher fdelity than pseudouridine in synthetic RNAs (demonstrates high error rates) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335462/pdf/41598_2022_Article_17249.pdf 22) LNP packaging of dsDNA: https://anandamide.substack.com/p/lnp-packaging-of-dsdna 23) IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222767/ 24) COVID-19 vaccine-associated mortality in the Southern Hemisphere: https://correlation- canada.org/covid-19-vaccine-associated-mortality-in-the-southern-hemisphere/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Find Monica:  Website: https://monicasdeepdives.com Twitter: https://twitter.com/monicaperezshow Rokfin: https://rokfin.com/deepdives Rumble: https://rumble.com/user/monicaperezshow YouTube: https://www.youtube.com/c/MonicaPerez  Shownotes: 1) EMA Quality Report - Rapporteurs-Rolling-Review-Report-Quality-COVID-19-mRNA-Vaccine- BioNTec.doc (live.com) 2) SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination: https://onlinelibrary.wiley.com/doi/10.1111/apm.13294 3) Biodistribution of mRNA COVID-19 vaccines in human breast milk https://www.thelancet.com/action/showPdf?pii=S2352-3964%2823%2900366-3 4) FDA - Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum https://www.fda.gov/media/144416/download 5) EMA Comirnaty Assessment Report - https://www.ema.europa.eu/en/documents/assessment- report/comirnaty-epar-public-assessment-report_en.pdf 6) Three decades of messenger RNA vaccine development - ScienceDirect 7) Frontiers | Are There Hidden Genes in DNA/RNA Vaccines? (frontiersin.org) 8) Effect of mRNA Vaccine Manufacturing Processes on Efficacy and Safety Still an Open Question | The BMJ 9) Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line (nih.gov) 10) dsDNA variance in Pfizer Docs - by Anandamide (substack.com) 11) COVID-19 primary series and booster vaccination and immune imprinting https://www.medrxiv.org/content/10.1101/2022.10.31.22281756v1.full.pdf 12) Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061025 13) A SYSTEMATIC REVIEW OF AUTOPSY FINDINGS IN DEATHS AFTER COVID-19 VACCINATION: https://zenodo.org/record/8120771 14) Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine (Cleveland Clinic Study): https://academic.oup.com/ofid/article/10/6/ofad209/7131292?login=false 15) Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents: https://pubmed.ncbi.nlm.nih.gov/36006288/ 16) Deep sequencing of the Moderna and Pfizer bivalent vaccines identifies contamination of expression vectors designed for plasmid amplification in bacteria | Kevin McKernan: https://rumble.com/v2c785k-march-8-2023.html?mref=umbzp&mc=dprv6 17) BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis: https://onlinelibrary.wiley.com/doi/10.1111/eci.13759 18) SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents: https://jamanetwork.com/journals/jamacardiology/fullarticle/2791253 19) Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults: https://www.sciencedirect.com/science/article/pii/S0264410X22010283 20) N1 methylpseudouridine is incorporated with higher fdelity than pseudouridine in synthetic RNAs (demonstrates high error rates) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335462/pdf/41598_2022_Article_17249.pdf 22) LNP packaging of dsDNA: https://anandamide.substack.com/p/lnp-packaging-of-dsdna 23) IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222767/ 24) COVID-19 vaccine-associated mortality in the Southern Hemisphere: https://correlation- canada.org/covid-19-vaccine-associated-mortality-in-the-southern-hemisphere/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Synthetic biology and the Great Deception. Adolph Hitler and psychology. The heart is deceptive and evil because its emotional nature is easily provoked and manipulated. Warfare and covert operations. The art of deception to deploy a secret weapon. Sasha Latypova explains the Department of Defense involvement in the Covid response. Excerpts from a Danish study titled, “Batch-Dependent Safety of The Bnt162b2 MRNA Covid-19 Vaccine”, and the taking down of another study of covid vaccine autopsies that found 74% of deaths were caused by vaccine. Karen Kingston and Ana Mihalcea interview with Maria Zeee to discuss some elements of bioweapon masquerading as a vaccine. Todd Callender and Lee Vleet interview on SGT Report discloses the use of mosquitoes to spread bioweapon love.

Episode 21: Cardiovascular Effects of mRNA COVID-19 Vaccines in Adolescents (Preprint Thai Study) In this prospective cohort study of school children receiving BNT162b2 mRNA COVID-19 vaccines, researchers from Thailand have stunning data. Let's review. DrBeen: Medical Education Onlinehttps://www.drbeen.com/ FLCCC | Front Line COVID-19 Critical Care Alliancehttps://covid19criticalcare.com/URL list from Monday, Aug. 15 2022 Cardiovascular Effects of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents[v1] | Preprintshttps://www.preprints.org/manuscript/202208.0151/v1 Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 | Vaccination | JAMA | JAMA Networkhttps://jamanetwork.com/journals/jama/fullarticle/2788346Related document to the above letterhttps://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-06/05-COVID-Wallace-508.pdf Myocarditis after BNT162b2 Vaccination in Israeli Adolescents | NEJMhttps://www.nejm.org/doi/full/10.1056/NEJMc2116999 Persistent Cardiac Magnetic Resonance Imaging Findings in a Cohort of Adolescents with Post-Coronavirus Disease 2019 mRNA Vaccine Myopericarditis - The Journal of Pediatricshttps://www.jpeds.com/article/S0022-3476(22)00282-7/fulltext#%20 CPK-MB test - Wikipediahttps://en.wikipedia.org/wiki/CPK-MB_test Disclaimer:This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only. Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional. covid19dr beenflccclong story shortmrna vaccines

Effectiveness of the BNT162b2 mRNA COVID-19 vaccine among adolescents with juvenile-onset inflammatory rheumatic diseases (IRDs).Dr Amit Ziv and Prof Yosef Uziel (both Tel Aviv University and Meir Medical Center, Israel) join Dr Herman Tam to discuss the effectiveness of the BNT162b2 mRNA COVID-19 vaccine in preventing infection in adolescents with juvenile-onset IRDs.You can read this article in Rheumatology.Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram. Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

In his weekly clinical update Dr. Griffin discusses the four things to know about RSV, the burden of respiratory syncytial virus in healthy term-born infants in Europe, the diagnostic accuracy of rapid diagnostic tests for Ebola virus disease, evaluating the accuracy of self-collected swabs for the diagnosis of monkeypox, tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations, acute and postacute sequelae associated with SARS-CoV-2 reinfection, clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients, effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy, maternal antibody response and transplacental transfer following SARS-CoV-2 infection or vaccination in pregnancy, impact of community masking on COVID-19, Lifting Universal Masking in Schools – Covid-19 Incidence among Students and Staff, systematic review of the clinical effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 in immunocompromised patients, comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in patients in the community, early adoption of anti–SARS-CoV-2 pharmacotherapies among us veterans with mild to moderate COVID-19, evaluation of viral and symptom rebound differences between Paxlovid and untreated COVID-19 participants, monoclonal antibodies for treatment of SARS-CoV-2 infection during pregnancy, twice daily oral zinc in the treatment of patients with COVID-19, cognitive deficits in long Covid-19, severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration, and long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Four things to know about RSV (Gates Foundation) The burden of RSV in healthy term-born infants in Europe (The Lancet) Diagnostic accuracy of rapid tests for Ebola (CMI) Accuracy of self-collected swabs for diagnosis of Monkeypox (CID) Tecovirimat is effective against human monkeypox virus in vitro (Nature) Acute and postacute sequelae associated with SARS-CoV-2 reinfection (NatureMedicine) SARS-CoV-2 infection and recovery in lung transplant recipients (Transplant Infectious Diseases) Effectiveness of third COVID-19 vaccination during pregnancy (Nature Communications) Maternal antibody response and transplacental transfer following infection or vaccination (CID) Impact of community masking on COVID-19 (Science) Lifting universal masking in schools (NEJM) Bebtelovimab fact sheet for providers (FDA) Effectiveness of Tixagevimab/Cilgavimab for prophylaxis of COVID-19 (medRxiv) Effectiveness of Sotrovimab and Molnupiravir for prevention of severe COVID-19 outcomes (BMJ) Early adoption of Anti–SARS-CoV-2 pharmacotherapies among US veterans (JAMA) PAXLOVID patient eligibility screening checklist (FDA) Viral and symptom rebound differences between Paxlovid and untreated COVID-19 participants (medRxiv) Monoclonal antibodies for treatment of SARS-CoV-2 during pregnancy (Annals of Internal Medicine) Remdesivir fact sheet for providers (Veklury)  Twice daily oral zinc in the treatment of patients with COVID-19 (CID)  Cognitive deficits in long COVID-19 (NEJM) Severe Neuro-COVID associated with peripheral immune signatures, autoimmunity and neurodegeneration (Nature Communications) Long-lasting symptoms after an acute COVID-19 Infection (JAMA) Contribute to our MicrobeTV fundraiser at PWB Dr. Griffin's treatment guide (pdf) Letters read on TWiV 955 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv

In this 143rd in a series of live discussions with Bret Weinstein and Heather Heying (both PhDs in Biology), we discuss the state of the world through an evolutionary lens.This week, we discuss how some stories diagnose a system: What does it mean when a college declares its (non-racist) professors racist? What does it mean when journalists only recognize election fraud if it works against their team? What does it mean when “science” is invoked only to support foregone conclusions? Discussing these and more examples from the last two and a half years of Covid, we talk about the need for functional journalism, science, higher ed, and government, and of “skepticism kill switches.” How do you get people to stop being skeptical? Tell them that asking questions renders them a racist, a murderer, or a TERF.Our store:  https://www.darkhorsestore.orgOur book: A Hunter-Gatherer's Guide to the 21st Century: https://www.amazon.com/Hunter-Gatherers-Guide-21st-Century-Challenges/dp/0593086880/). Signed copies available here: https://darvillsbookstore.indielite.orgOur Patreons: https://www.patreon.com/heatherheying, https://www.patreon.com/bretweinsteinHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur sponsors:BUBS Naturals: High-quality, sustainably sourced collagen protein, MCT oil, and more, from a company with a conscience. DIE YOUNG AS LATE AS POSSIBLE. Go to bubsnaturals.com/DARKHORSE for 20% off your order.Sole: excellent, consciously made shoes and footbeds. Visit www.yoursole.com/darkhorse, and if you live in a ZIP code (US) / Postal Code (Canada) where Sole hasn't shipped to, you'll receive a free Performance Medium footbed. MUDWTR: is a coffee alternative with mushrooms and herbs (and cacao!) and is delicious, with 1/7 the caffeine as coffee. Visit www.mudwtr.com/darkhorse and use DARKHORSE at check out for 15% off.Mentioned in this episode:Mansanguan et al 2022. Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents. Tropical Medicine and Infectious Disease, 7(8): 196. https://www.mdpi.com/2414-6366/7/8/196Toronto-area shop teacher shows up for class with giant prosthetic breasts: https://twitter.com/lovelyti/status/1572653516153581568?s=20&t=34smdHt5Ef0ZTcxThknc7wTimestamps:(00:00) Welcome and announcements(07:00) Sponsors(14:20) Some stories diagnose the system(32:22) Capture(41:35) Government capture(01:01:30) Breaking Points on lab leak(01:18:00) Journalists(01:23:50) Conclusion and end point of this analysis(01:26:44) Giant breasted teacher(01:42:15) Wrap upSupport the show

Greetings Listeners! This is a short outtake from the previous episode with Dr. Francis Christian, MD. In this segment Dr. Christian provides us with a brief synopsis on the mRNA vaccines. I know that many of you have grown weary of such discussions and as such I removed this portion from our otherwise buoyant and uplifting message of hope and inspiration. To reference the paper Dr. Christian refers to, please visit: Cardiovascular Effects of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents

Allmennlege Sjur Even Aunmo fikk sparken som fastlegevikar fordi han fortalte pasienter at COVID-19-vaksinen kan gi bivirkninger. Dette er noe han plikter å gjøre ifølge Pasient- og brukerrettighetsloven § 4. Aunmo har satt seg grundig inn i forskningen på disse vaksinene, og påpeker at de for det første er eksperimentelle på dette stadiet. Videre er det Pfizer selv som har finansiert sin studie, en ansatt fikk sparken fordi hun varslet om at blindingen (anonymiseringen) var brutt, personer har blitt tatt ut av studien uten at det er oppgitt noen god grunn og rådataene for studien er ikke offentliggjort. Selv har han sett flere bivirkninger, som kraftige menstruasjonsblødninger, hjerteproblemer og alvorlige nevrologiske bivirkninger. Han frykter at underrapportering kan medføre at bivirkningstallene fra Statens legemiddelverk er for lave. KILDER:› COVID-19 • https://clinicaltrials.gov/ct2/show/NCT04368728 • https://clinicaltrials.gov/ct2/show/NCT04470427 • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine • Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase • https://covid-nma.com/vaccines/variants/ • https://covid-nma.com/vaccines/index.php?search_by=1&search_input=1273&submit=Validate#moteur_recherche • How significant is the Ventavia scandal? • Covid-19: Researcher blows the whistle on data integrity issues in Pfizer's vaccine trial • CDC-vurdering av Modernas studie • https://www.bmj.com/company/newsroom/editors-call-for-covid-19-vaccine-and-treatment-data-to-be-available-for-public-scrutiny/ • https://www.nrk.no/norge/norges-forste-koronavaksine-settes-1.15304159, lest 20.3.22 • https://tidsskriftet.no/2021/05/originalartikkel/dodsfall-i-sykehjem-etter-covid-19-vaksine ◦ https://www.fhi.no/hn/helseregistre-og-registre/dodsarsaksregisteret/tall-for-covid-19-assosierte-dodsfall-i-dodsarsaksregisteret-i-2020/ ◦ https://legemiddelverket.no/Documents/Bivirkninger%20og%20sikkerhet/Rapporter%20og%20oversikter/Koronavaksiner/20211028%20Rapport%20over%20meldte%20bivirkninger%20av%20koronavaksine.pdf ◦ Surveillance for safety after immunization; vaccine adverse event reporting system (VAERS) - United States 1991-2001 ◦ Mandatory Reporting of Infectious Diseases by Clinicians ◦ Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018 ◦ https://www.nrk.no/livsstil/_-en-medisinsk-katastrofe-1.10880384 ◦ https://legemiddelverket.no/nyheter/bivirkninger-av-vaksiner-hva-lerte-vi-av-pandemien-i-2009#ble-det-meldt-noen-d%C3%B8dsfall? ◦ The illusion of evidence based medicine ‧ Amerikanske Centers for Disease Control om underrapportering ‧ Studie fra det medisinske tidsskriftet JAMA om underrapportering ‧ Studie fra det medisinske tidsskriftet Vaccine om underrapportering ‧ Fra det amerikanske registrerings-systemet VAERS om deres system ‧ Randomised Clinical Trials of COVID-19 Vaccines: Do Adenovirus-Vector Vaccines Have Beneficial Non-Specific Effects? ‧ Lancet 2022. Samlestudie RCT. Obs: Preprrint, ikke fagfallevurdert enda. Signifikant og stor forskjell mellom Pfizer/Moderna og svekket-virus-vaksiner.› FETT • Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis • Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73) • Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease • The effect of replacing saturated fat with mostly n-6 polyunsaturated fat on coronary heart disease: a meta-analysis of randomised controlled trials • Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art Review • http://dx.doi.org/10.1136/openhrt-2014-000196 • Fat or fiction: the diet-heart hypothesis | BMJ Evidence-Based Medicine • https://www.mn.uio.no/ibv/tjenester/kunnskap/plantefys/leksikon/h/herdet-fett.html • 4-Hydroxynonenal-Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease • https://doi.org/10.1016/j.freeradbiomed.2006.07.021 ◦ Dietary stearic acid regulates mitochondria in vivo in humans - Nature Communications ◦ 33.9 10.17140/AFTNSOJ-1-123 Oxidation of Polyunsaturated Fatty Acids and its Impact on Food Quality and Human Health ◦ Dietary oxidized n-3 PUFA induce oxidative stress and inflammation: role of intestinal absorption of 4-HHE and reactivity in intestinal cells ◦ Effect of the Type of Frying Culinary Fat on Volatile Compounds Isolated in Fried Pork Loin Chops by Using SPME-GC-MS› STATINER • BMJ RCT sysrew/meta Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews • The effect of statins on average survival in randomised trials, an analysis of end point postponement • JAMA RCT-meta 2010 - Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants • https://www.felleskatalogen.no/medisin/lipitor-upjohn-eesv-pfizer-560999 • https://www.felleskatalogen.no/medisin/zocor-organon-565655 • https://www.legemiddelhandboka.no/L8.15.1/Statiner • Statins - a call for transparent data - The BMJ • Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women's Health Initiative› KJØTT • Effect of Lower Versus Higher Red Meat Intake on Cardiometabolic and Cancer Outcomes A Systematic Review of Randomized Trials • Total red meat intake of ≥0.5 servings/d does not negatively influence cardiovascular disease risk factors: a systemically searched meta-analysis of randomized controlled trials› KOLESTEROL • Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review • Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia • PMID: 18277343 ApoB/ApoA1 ratio and subclinical atherosclerosis ◦ Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages ◦ Cigarette Smoking Potentiates Endothelial Dysfunction of Forearm Resistance Vessels in Patients With Hypercholesterolemia: Role of Oxidized LDL ◦ Passive Smoking Induces Atherogenic Changes in Low-Density Lipoprotein ◦ Smoking and smoking cessation—The relationship between cardiovascular disease and lipoprotein metabolism: A review ◦ Smoking and Cardiovascular Disease ◦ LDL biochemical modifications: a link between atherosclerosis and aging ◦ Association Between Circulating Oxidized LDL and Atherosclerotic Cardiovascular Disease: A Meta-analysis of Observational Studies› KARBOHYDRAT • https://www.helsedirektoratet.no/rapporter/anbefalinger-om-kosthold-ernaering-og-fysisk-aktivitet/Anbefalinger%20om%20kosthold%20ern%C3%A6ring%20og%20fysisk%20aktivitet.pdf/_/attachment/inline/2f5d80b2-e0f7-4071-a2e5-3b080f99d37d:2aed64b5b986acd14764b3aa7fba3f3c48547d2d/Anbefalinger%20om%20kosthold%20ern%C3%A6ring%20og%20fysisk%20aktivitet.pdf› DIABETES • JAMA WMI 2006Low-Fat Dietary Pattern and Risk of Cardiovascular DiseaseThe Women's Health Initiative Randomized Controlled Dietary Modification Trial – se side 661, økt hjerte/kar-risk sfa. Lavfett-diett • AmJourClinNutr WMI 2011 Effects of a low-fat dietary intervention on glucose, insulin, and insulin resistance in the Women's Health Initiative (WHI) Dietary Modification trial • AOCS Lipids (lavranket journal) Carbohydrate Restriction has a More Favorable Impact on the Metabolic Syndrome than a Low Fat Diet • Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease- ArtThromVas prospektiv kohort • Glycation as an atherogenic modification of LDL : Current Opinion in Lipidology • Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? • Loss of Endothelial Glycocalyx During Acute Hyperglycemia Coincides With Endothelial Dysfunction and Coagulation Activation In Vivo› DIABETES-DEMENS • AgeingResearchRewiew 2019 sysrew/meta 144 prospektive studier – 58 % økt risiko demens • Int. Med. Journ. 2012 meta-analyse av prospektive kohorter dia-demens-risk 51 % økning demens • Lancet Neurology 2006, sysrew lavere evidensgrad. Risk of dementia in diabetes mellitus: a systematic review • Diabetes mellitus and the risk of dementia - The Rotterdam Study – prospektiv kohort • JDST 2008 Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed • MDPI 2015 Evaluating the Association between Diabetes, Cognitive Decline and Dementia • Ketone Bodies Promote Amyloid-β1–40 Clearance in a Human in Vitro Blood–Brain Barrier Model - 2020 • Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implication - 2018 • APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline - 2020› HJERTE- OG KAR-SYKDOM • 10.1001/jamacardio.2020.7073 Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women› PLANTE-ANTINÆRINGSSTOFF OG VERN • Food Chemistry 2008 Bioaccessibility of Ca, Mg, Mn and Cu from whole grain tea-biscuits: Impact of proteins, phytic acid and polyphenols • Phytate in foods and significance for humans: food sources, intake, processing, bioavailability, protective role and analysis. Mol Nutr Food Res. 2009 Sep;53 Suppl 2:S330-75. • Oxalate content of foods and its effect on humans • Lectins as plant defense proteins • Effects of wheat germ agglutinin on human gastrointestinal epithelium: Insights from an experimental model of immune/epithelial cell interaction • Ingestion of subthreshold doses of environmental toxins induces ascending Parkinsonism in the rat • Identification of intact peanut lectin in peripheral venous blood • Do dietary lectins cause disease? BMJ • Lectin binding of endometrium in women with unexplained infertility • Changes in organs and tissues induced by feeding of purified kidney bean (Phaseolus vulgaris) lectins • Insecticidal Activity of Plant Lectins and Potential Application in Crop Protection • Bound Lectins that Mimic Insulin Produce Persistent Insulin-Like Activities • Contribution of leptin receptor N-linked glycans to leptin binding • Potato lectin activates basophils and mast cells of atopic subjects by its interaction with core chitobiose of cell-bound non-specific immunoglobulin E • 3.0.CO;2-T Dietary lectins can induce in vitro release of IL-4 and IL-13 from human basophils • Secondary Oxalate Nephropathy: A Systematic Review • The effect of tea on iron absorption • PMID: 1862 Disler PB, Lynch SR, Torrance JD, et al. The mechanism of the inhibition of iron absorption by tea. The South African Journal of Medical Sciences. 1975 ;40(4):109-116. • Effects of saponins and glycoalkaloids on the permeability and viability of mammalian intestinal cells and on the integrity of tissue preparationsin vitro • The biological action of saponins in animal systems: a review • Small Amounts of Gluten in Subjects With Suspected Nonceliac Gluten Sensitivity: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial ◦ Obs: Kapsler brukt i studien ble supplert av legemiddelfirmaet Giuliani, som lager glutenfritt brød.› LEKK TARM • Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines • Gliadin Induces an Increase in Intestinal Permeability and Zonulin Release by Binding to the Chemokine Receptor CXCR3 • AmJourClinNu 2009 Cancer incidence in vegetarians: results from the European Prospective Investigation into Cancer and Nutrition (EPIC-Oxford) • FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction • 73.3 10.12688/f1000research.20510.1 All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases› LAVKARB • Effects of Low-Carbohydrate vs Low-Fat Diets on Weight Loss and Cardiovascular Risk Factors • BritJourNutr 2013 RCT-meta Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials • AnnIntMed 2004 A Low-Carbohydrate, Ketogenic Diet versus a Low-Fat Diet To Treat Obesity and Hyperlipidemia: A Randomized, Controlled Trial • JAMAIntMed A Randomized Trial of a Low-Carbohydrate Diet vs Orlistat Plus a Low-Fat Diet for Weight Loss • NEJM RCT 2006 A Low-Carbohydrate as Compared with a Low-Fat Diet in Severe Obesity • Short-term effects of severe dietary carbohydrate-restriction advice in Type 2 diabetes—a randomized controlled trial • Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: randomized trial • Effects of a low-carbohydrate diet on weight loss and cardiovascular risk factor in overweight adolescents • Comparison of the Atkins, Zone, Ornish, and LEARN Diets for Change in Weight and Related Risk Factors Among Overweight Premenopausal WomenThe A TO Z Weight Loss Study: A Randomized Trial • Efficacy and Safety of a High Protein, Low Carbohydrate Diet for Weight Loss in Severely Obese Adolescents • Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial› FRUKTOSE • JourHepatology 2021 Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial • Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial› KETOGENISITET/KREFT • https://oslo-universitetssykehus.no/behandlinger/pet-undersokelse • https://stanfordhealthcare.org/medical-tests/p/pet-scan/what-to-expect.html • https://www.sciencedirect.com/topics/medicine-and-dentistry/warburg-effect • The Warburg Effect: How Does it Benefit Cancer Cells? • NutrCanc 2019 Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study • Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803 • Ketogenic diet in cancer therapy› IATROGEN SKADE • https://tidsskriftet.no/2000/10/kronikk/uheldige-hendelser-i-helsetjenesten-forebygging-og-handteringDownload this episodeRecorded: 2022-05-02Published: 2022-05-22

Allmennlege Sjur Even Aunmo fikk sparken som fastlegevikar fordi han fortalte pasienter at COVID-19-vaksinen kan gi bivirkninger. Dette er noe han plikter å gjøre ifølge Pasient- og brukerrettighetsloven § 4. Aunmo har satt seg grundig inn i forskningen på disse vaksinene, og påpeker at de for det første er eksperimentelle på dette stadiet. Videre er det Pfizer selv som har finansiert sin studie, en ansatt fikk sparken fordi hun varslet om at blindingen (anonymiseringen) var brutt, personer har blitt tatt ut av studien uten at det er oppgitt noen god grunn og rådataene for studien er ikke offentliggjort. Selv har han sett flere bivirkninger, som kraftige menstruasjonsblødninger, hjerteproblemer og alvorlige nevrologiske bivirkninger. Han frykter at underrapportering kan medføre at bivirkningstallene fra Statens legemiddelverk er for lave. KILDER:› COVID-19 • https://clinicaltrials.gov/ct2/show/NCT04368728 • https://clinicaltrials.gov/ct2/show/NCT04470427 • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine • Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase • https://covid-nma.com/vaccines/variants/ • https://covid-nma.com/vaccines/index.php?search_by=1&search_input=1273&submit=Validate#moteur_recherche • How significant is the Ventavia scandal? • Covid-19: Researcher blows the whistle on data integrity issues in Pfizer's vaccine trial • CDC-vurdering av Modernas studie • https://www.bmj.com/company/newsroom/editors-call-for-covid-19-vaccine-and-treatment-data-to-be-available-for-public-scrutiny/ • https://www.nrk.no/norge/norges-forste-koronavaksine-settes-1.15304159, lest 20.3.22 • https://tidsskriftet.no/2021/05/originalartikkel/dodsfall-i-sykehjem-etter-covid-19-vaksine ◦ https://www.fhi.no/hn/helseregistre-og-registre/dodsarsaksregisteret/tall-for-covid-19-assosierte-dodsfall-i-dodsarsaksregisteret-i-2020/ ◦ https://legemiddelverket.no/Documents/Bivirkninger%20og%20sikkerhet/Rapporter%20og%20oversikter/Koronavaksiner/20211028%20Rapport%20over%20meldte%20bivirkninger%20av%20koronavaksine.pdf ◦ Surveillance for safety after immunization; vaccine adverse event reporting system (VAERS) - United States 1991-2001 ◦ Mandatory Reporting of Infectious Diseases by Clinicians ◦ Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018 ◦ https://www.nrk.no/livsstil/_-en-medisinsk-katastrofe-1.10880384 ◦ https://legemiddelverket.no/nyheter/bivirkninger-av-vaksiner-hva-lerte-vi-av-pandemien-i-2009#ble-det-meldt-noen-d%C3%B8dsfall? ◦ The illusion of evidence based medicine ‧ Amerikanske Centers for Disease Control om underrapportering ‧ Studie fra det medisinske tidsskriftet JAMA om underrapportering ‧ Studie fra det medisinske tidsskriftet Vaccine om underrapportering ‧ Fra det amerikanske registrerings-systemet VAERS om deres system ‧ Randomised Clinical Trials of COVID-19 Vaccines: Do Adenovirus-Vector Vaccines Have Beneficial Non-Specific Effects? ‧ Lancet 2022. Samlestudie RCT. Obs: Preprrint, ikke fagfallevurdert enda. Signifikant og stor forskjell mellom Pfizer/Moderna og svekket-virus-vaksiner.› FETT • Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis • Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73) • Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease • The effect of replacing saturated fat with mostly n-6 polyunsaturated fat on coronary heart disease: a meta-analysis of randomised controlled trials • Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art Review • http://dx.doi.org/10.1136/openhrt-2014-000196 • Fat or fiction: the diet-heart hypothesis | BMJ Evidence-Based Medicine • https://www.mn.uio.no/ibv/tjenester/kunnskap/plantefys/leksikon/h/herdet-fett.html • 4-Hydroxynonenal-Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease • https://doi.org/10.1016/j.freeradbiomed.2006.07.021 ◦ Dietary stearic acid regulates mitochondria in vivo in humans - Nature Communications ◦ 33.9 10.17140/AFTNSOJ-1-123 Oxidation of Polyunsaturated Fatty Acids and its Impact on Food Quality and Human Health ◦ Dietary oxidized n-3 PUFA induce oxidative stress and inflammation: role of intestinal absorption of 4-HHE and reactivity in intestinal cells ◦ Effect of the Type of Frying Culinary Fat on Volatile Compounds Isolated in Fried Pork Loin Chops by Using SPME-GC-MS› STATINER • BMJ RCT sysrew/meta Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews • The effect of statins on average survival in randomised trials, an analysis of end point postponement • JAMA RCT-meta 2010 - Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants • https://www.felleskatalogen.no/medisin/lipitor-upjohn-eesv-pfizer-560999 • https://www.felleskatalogen.no/medisin/zocor-organon-565655 • https://www.legemiddelhandboka.no/L8.15.1/Statiner • Statins - a call for transparent data - The BMJ • Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women's Health Initiative› KJØTT • Effect of Lower Versus Higher Red Meat Intake on Cardiometabolic and Cancer Outcomes A Systematic Review of Randomized Trials • Total red meat intake of ≥0.5 servings/d does not negatively influence cardiovascular disease risk factors: a systemically searched meta-analysis of randomized controlled trials› KOLESTEROL • Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review • Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia • PMID: 18277343 ApoB/ApoA1 ratio and subclinical atherosclerosis ◦ Cigarette smoking renders LDL susceptible to peroxidative modification and enhanced metabolism by macrophages ◦ Cigarette Smoking Potentiates Endothelial Dysfunction of Forearm Resistance Vessels in Patients With Hypercholesterolemia: Role of Oxidized LDL ◦ Passive Smoking Induces Atherogenic Changes in Low-Density Lipoprotein ◦ Smoking and smoking cessation—The relationship between cardiovascular disease and lipoprotein metabolism: A review ◦ Smoking and Cardiovascular Disease ◦ LDL biochemical modifications: a link between atherosclerosis and aging ◦ Association Between Circulating Oxidized LDL and Atherosclerotic Cardiovascular Disease: A Meta-analysis of Observational Studies› KARBOHYDRAT • https://www.helsedirektoratet.no/rapporter/anbefalinger-om-kosthold-ernaering-og-fysisk-aktivitet/Anbefalinger%20om%20kosthold%20ern%C3%A6ring%20og%20fysisk%20aktivitet.pdf/_/attachment/inline/2f5d80b2-e0f7-4071-a2e5-3b080f99d37d:2aed64b5b986acd14764b3aa7fba3f3c48547d2d/Anbefalinger%20om%20kosthold%20ern%C3%A6ring%20og%20fysisk%20aktivitet.pdf› DIABETES • JAMA WMI 2006Low-Fat Dietary Pattern and Risk of Cardiovascular DiseaseThe Women's Health Initiative Randomized Controlled Dietary Modification Trial – se side 661, økt hjerte/kar-risk sfa. Lavfett-diett • AmJourClinNutr WMI 2011 Effects of a low-fat dietary intervention on glucose, insulin, and insulin resistance in the Women's Health Initiative (WHI) Dietary Modification trial • AOCS Lipids (lavranket journal) Carbohydrate Restriction has a More Favorable Impact on the Metabolic Syndrome than a Low Fat Diet • Small Dense Low-Density Lipoprotein-Cholesterol Concentrations Predict Risk for Coronary Heart Disease- ArtThromVas prospektiv kohort • Glycation as an atherogenic modification of LDL : Current Opinion in Lipidology • Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? • Loss of Endothelial Glycocalyx During Acute Hyperglycemia Coincides With Endothelial Dysfunction and Coagulation Activation In Vivo› DIABETES-DEMENS • AgeingResearchRewiew 2019 sysrew/meta 144 prospektive studier – 58 % økt risiko demens • Int. Med. Journ. 2012 meta-analyse av prospektive kohorter dia-demens-risk 51 % økning demens • Lancet Neurology 2006, sysrew lavere evidensgrad. Risk of dementia in diabetes mellitus: a systematic review • Diabetes mellitus and the risk of dementia - The Rotterdam Study – prospektiv kohort • JDST 2008 Alzheimer's Disease is Type 3 Diabetes—Evidence Reviewed • MDPI 2015 Evaluating the Association between Diabetes, Cognitive Decline and Dementia • Ketone Bodies Promote Amyloid-β1–40 Clearance in a Human in Vitro Blood–Brain Barrier Model - 2020 • Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implication - 2018 • APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline - 2020› HJERTE- OG KAR-SYKDOM • 10.1001/jamacardio.2020.7073 Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women› PLANTE-ANTINÆRINGSSTOFF OG VERN • Food Chemistry 2008 Bioaccessibility of Ca, Mg, Mn and Cu from whole grain tea-biscuits: Impact of proteins, phytic acid and polyphenols • Phytate in foods and significance for humans: food sources, intake, processing, bioavailability, protective role and analysis. Mol Nutr Food Res. 2009 Sep;53 Suppl 2:S330-75. • Oxalate content of foods and its effect on humans • Lectins as plant defense proteins • Effects of wheat germ agglutinin on human gastrointestinal epithelium: Insights from an experimental model of immune/epithelial cell interaction • Ingestion of subthreshold doses of environmental toxins induces ascending Parkinsonism in the rat • Identification of intact peanut lectin in peripheral venous blood • Do dietary lectins cause disease? BMJ • Lectin binding of endometrium in women with unexplained infertility • Changes in organs and tissues induced by feeding of purified kidney bean (Phaseolus vulgaris) lectins • Insecticidal Activity of Plant Lectins and Potential Application in Crop Protection • Bound Lectins that Mimic Insulin Produce Persistent Insulin-Like Activities • Contribution of leptin receptor N-linked glycans to leptin binding • Potato lectin activates basophils and mast cells of atopic subjects by its interaction with core chitobiose of cell-bound non-specific immunoglobulin E • 3.0.CO;2-T Dietary lectins can induce in vitro release of IL-4 and IL-13 from human basophils • Secondary Oxalate Nephropathy: A Systematic Review • The effect of tea on iron absorption • PMID: 1862 Disler PB, Lynch SR, Torrance JD, et al. The mechanism of the inhibition of iron absorption by tea. The South African Journal of Medical Sciences. 1975 ;40(4):109-116. • Effects of saponins and glycoalkaloids on the permeability and viability of mammalian intestinal cells and on the integrity of tissue preparationsin vitro • The biological action of saponins in animal systems: a review • Small Amounts of Gluten in Subjects With Suspected Nonceliac Gluten Sensitivity: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial ◦ Obs: Kapsler brukt i studien ble supplert av legemiddelfirmaet Giuliani, som lager glutenfritt brød.› LEKK TARM • Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines • Gliadin Induces an Increase in Intestinal Permeability and Zonulin Release by Binding to the Chemokine Receptor CXCR3 • AmJourClinNu 2009 Cancer incidence in vegetarians: results from the European Prospective Investigation into Cancer and Nutrition (EPIC-Oxford) • FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction • 73.3 10.12688/f1000research.20510.1 All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases› LAVKARB • Effects of Low-Carbohydrate vs Low-Fat Diets on Weight Loss and Cardiovascular Risk Factors • BritJourNutr 2013 RCT-meta Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials • AnnIntMed 2004 A Low-Carbohydrate, Ketogenic Diet versus a Low-Fat Diet To Treat Obesity and Hyperlipidemia: A Randomized, Controlled Trial • JAMAIntMed A Randomized Trial of a Low-Carbohydrate Diet vs Orlistat Plus a Low-Fat Diet for Weight Loss • NEJM RCT 2006 A Low-Carbohydrate as Compared with a Low-Fat Diet in Severe Obesity • Short-term effects of severe dietary carbohydrate-restriction advice in Type 2 diabetes—a randomized controlled trial • Effects of a low carbohydrate diet on energy expenditure during weight loss maintenance: randomized trial • Effects of a low-carbohydrate diet on weight loss and cardiovascular risk factor in overweight adolescents • Comparison of the Atkins, Zone, Ornish, and LEARN Diets for Change in Weight and Related Risk Factors Among Overweight Premenopausal WomenThe A TO Z Weight Loss Study: A Randomized Trial • Efficacy and Safety of a High Protein, Low Carbohydrate Diet for Weight Loss in Severely Obese Adolescents • Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial› FRUKTOSE • JourHepatology 2021 Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial • Effects of fructose restriction on liver steatosis (FRUITLESS); a double-blind randomized controlled trial› KETOGENISITET/KREFT • https://oslo-universitetssykehus.no/behandlinger/pet-undersokelse • https://stanfordhealthcare.org/medical-tests/p/pet-scan/what-to-expect.html • https://www.sciencedirect.com/topics/medicine-and-dentistry/warburg-effect • The Warburg Effect: How Does it Benefit Cancer Cells? • NutrCanc 2019 Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study • Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803 • Ketogenic diet in cancer therapy› IATROGEN SKADE • https://tidsskriftet.no/2000/10/kronikk/uheldige-hendelser-i-helsetjenesten-forebygging-og-handteringOpptaksdato: 2022-05-02Publiseringsdato: 2022-05-22Last ned episoden

Det er dessverre ikke uvanlig at helseinstitusjoner blir mål i krigsrammede områder, og vi ser også dette i Ukraina. Det foreligger enda mer forskning på covid-19-vaksinene, bivirkninger og immunitet. WHO oppfordrer dessuten til å være obs på at SARS-CoV-2 også forekommer blant ville dyr. Hvordan bør akillesseneruptur behandles? En sunn livsstil virker beskyttende mot å utvikle Alzheimers sykdom, men det øker også sjansen for å leve lenge. Når høy alder er en viktig risikofaktor for å utvikle Alzheimers sykdom, betyr det at de to utjevner hverandre? Og hva har hiphop og helse med hverandre å gjøre? Are Brean forteller om dette og mer i ukens episode.Tilbakemeldinger kan sendes til stetoskopet@tidsskriftet.no.      Stetoskopet produseres av Caroline Ulvin Johansson, Are Brean og Julie Didriksen ved Tidsskrift for Den norske legeforening. Ansvarlig redaktør er Are Brean.      Jingle og lydteknikk: Håkon Braaten / Moderne media   Coverillustrasjon: Stephen LeeArtikler nevnt:Seven days in medicine: 6-12 April 2022SURVEILLANCE SYSTEM FOR ATTACKS ON HEALTH CARE (SSA)Targeting healthcare in war: a tragically tried and tested strategy that humanity must disown—an essay by Jonathan KaplanRisk of Appendicitis After mRNA COVID-19 Vaccination in a Danish PopulationSARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million ResidentsRates of COVID-19 Among Unvaccinated Adults With Prior COVID-19Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or OlderWHO Urges Monitoring SARS-CoV-2 in Wildlife to Prevent Animal Reservoirs Nonoperative or Surgical Treatment of Acute Achilles' Tendon RuptureAcute Achilles' Tendon Rupture — Surgery or No Surgery Association of Familial Hypercholesterolemia and Statin Use With Risk of Dementia in Norway Healthy lifestyle and life expectancy with and without Alzheimer's dementia: population based cohort study Healthy lifestyles and more life years without dementia Association of Prenatal Exposure to Early-Life Adversity With Neonatal Brain Volumes at Birth Sixty seconds on . . . hip hop health

Edited by Drs L Ferguson and Z Jiyad.Narrated by Dr V Pinder.1) Evaluation of watchful waiting and tumour behaviour in patients with BCC2) Methotrexate hampers immunogenicity to BNT162B2 MRNA COVID vaccine in immune mediated inflammatory disease3) Diagnostic utility of circumferential peripheral globules under dermoscopy in adults4) The safety and immunologic effectiveness of live varicella zoster vaccine in patients receiving anti-TNF inhibitor therapy5) A systematic review of the impact of genetic testing for familial melanoma i) primary and secondary preventative behaviours ii) psychosocial outcomes and attitudes6) Skin adverse events related to PPE: a systematic review and meta-analysis7) Cutaneous findings in Fanconi's anaemia8) Adenopathy and extensive skin patch overlying plasmocytoma (AESOP): 2 morphological variants.Advanced Strings, Sir William Perkin's school- Isla Galpin (1st violin), Hayun Lee (2nd violin), Miss Townsend (viola), Amélie Christian (cello) - Chanson de Matin by Edward Elgar (1857–1934)

Dr Peter A. McCullough, MD, MPH, is a board-certified cardiologist, internist, epidemiologist who has testified before committees of the US and multiple State Senates regarding the treatment of COVID-19 and management of the ongoing pandemic. He has been in practice for over 40 years as an active treating physician combined with a decorative academic career that has placed him the most published cardiologist of all time. Join us as we explore:If it is safe to vaccinate your children The very real risk of myocarditis If you can get C-19 twice, why vaccinating post-COVID infection is dangerous, a huge amount of false + cases, C-19's mass psychosis The overwhelming evidence natural immunity is “complete, robust and durable” and “infinitely” superior to vaccinationMENTIONS:Avolio, E., et al. (2021). The SARS-CoV-2 Spike protein disrupts human cardiac pericytes function through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease. Clinical science (London, England : 1979), 135(24), 2667–2689. https://doi.org/10.1042/CS20210735 SARS-CoV-2 mRNA Vaccination-Associated Myocarditis in Children Ages 12-17: A Stratified National Database Analysis. Tracy Beth Høeg, et al.medRxiv 2021.08.30.21262866; doi: https://doi.org/10.1101/2021.08.30.21...    Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. Frontiers in cardiovascular medicine, 8, 758996. https://doi.org/10.3389/fcvm.2021.758996 Choi, S., Lee, et al.  (2021). Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. Journal of Korean medical science, 36(40), e286. https://doi.org/10.3346/jkms.2021.36....Professor Mattias Desmet https://www.ugent.be/psync/en/who/des...Shedding of Infectious SARS-CoV-2 Despite VaccinationKasen et al. medRxiv 2021.07.31.21261387; doi: https://doi.org/10.1101/2021.07.31.21... 141 Studies Showing Natural Immunity (up from 128)https://brownstone.org/articles/79-re... https://www.thegatewaypundit.com/2021... “Risks of Vaccines for Those Recovered from COVID-19 – Krammer, Raw & Mathioudakis”https://www.americaoutloud.com/risks-...  Cohn, B. A., et al (2021). SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science (New York, N.Y.), eabm0620. Advance online publication. https://doi.org/10.1126/science.abm0620Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. Peter Nordström, et al. The Lancet Regional Health – Europe.  December 2021. https://www.thelancet.com/journals/la...  “Failure of Vaccines and Truth Revealed”. https://www.americaoutloud.com/failur... COVID-19-associated hospitalizations among vaccinated and unvaccinated adults ≥18 years – COVID-NET, 13 states, January 1 – July 24, 2021. Fiona P. Havers, et al. medRxiv 2021.08.27.21262356; doi:https://doi.org/10.1101/2021.08.27.21...Antigenic minimalism of SARS-CoV-2 is linked to surges in COVID-19 community transmission and vaccine breakthrough infections. A.J. Venkatakrishnan, et al. medRxiv 2021.05.23.21257668; doi:https://doi.org/10.1101/2021.05.23.21...Kostoff, R. N., et al. (2021). Why are we vaccinating children against COVID-19?. Toxicology reports, 8, 1665–1684. https://doi.org/10.1016/j.toxrep.2021...Disclaimer policy for all of our videos. https://madetothrive.co.za/terms-and-...

I to preprintartikler der spytt, urin og avføring fra flaggermus har blitt undersøkt for spor etter slektninger av SARS-CoV-2-viruset i henholdsvis Laos og Kina, kom man frem til overraskende funn. Og mens flere av de rikeste landene i verden er i gang med den tredje vaksinedosen, vet vi fortsatt ikke egentlig om det er nødvendig. Vi har tidligere fått høre om en studie som konkluderte med at det var en sammenheng mellom bruk av epidural og autismespekterforstyrrelser – og nå får denne studien svar på tiltale gjennom to store retrospektive kohortstudier. Fysisk aktivitet er bra for helsen, men hvor lenge må man være aktiv? Årets IG Nobelpris er dessuten delt ut til flere vinnere, deriblant for forskning på om en orgasme kan hjelpe mot tett nese, hva ånden vår lukter når vi ser voldelige eller skremmende scener på kino, og om skjegg beskytter mot slag i en slåsskamp. Sjefredaktør Are Brean forteller om dette og mer i sin gjennomgang av siste nytt fra andre generelle medisinskvitenskapelige tidsskrifter.Tilbakemeldinger kan sendes til stetoskopet@tidsskriftet.no. Stetoskopet produseres av Lisa Dahlbak Jacobsen, Are Brean og Julie Didriksen ved Tidsskrift for Den norske legeforening. Ansvarlig redaktør er Are Brean. Lydtekniker: Håkon Braaten / Moderne Media Coverillustrasjon: Stephen Lee Artikler nevnt: Closest known relatives of virus behind COVID-19 found in LaosCOVID vaccine immunity is waning — how much does that matter?Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 MonthsCOVID vaccine boosters: the most important questionsmRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of ConcernCOVID-vaccine booster shot shows promise in Israeli studyIn Gratitude for mRNA VaccinesMaintenance or Discontinuation of Antidepressants in Primary CareThe Pursuit and Maintenance of HappinessAssociation Between Epidural Analgesia During Labor and Risk of Autism Spectrum Disorders in OffspringAssociation of Labor Epidural Analgesia With Autism Spectrum Disorder in ChildrenAssociation of Epidural Analgesia During Labor and Delivery With Autism Spectrum Disorder in OffspringAssociation of physical activity intensity and bout length with mortality: An observational study of 79,503 UK Biobank participantsStudy that finds good sex clears a stuffed nose as well as a decongestant wins Ig Nobel prize for medicine

Jacinda Abdul-Mutakabbir (@jayCdoesID) and Jeannette Bouchard (@jlbouchard001) join Erin McCreary (@ErinMcCreary) to discuss COVID vaccines, including access to, confidence in, and hesitancy around them.    This episode was sponsored by an unrestricted educational grant from Janssen Therapeutics, Division of Janssen Products, LP References: Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383:2603-2615. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384:403-416. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 2021 Rosenblum HG, Hadler SC, Moulia D, et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1094-1099. DOI: http://dx.doi.org/10.15585/mmwr.mm7032e4external icon. Rapaka RR, Hammershaimb EA, Neuzil KM. Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines [published online ahead of print, 2021 Mar 6]. Clin Infect Dis. 2021;ciab213. doi:10.1093/cid/ciab213 ACIP Website: https://www.cdc.gov/vaccines/acip/index.html Marcelin JR, Swartz TH, Bernice F, et al. Addressing and Inspiring Vaccine Confidence in Black, Indigenous, and People of Color (BIPOC) during the COVID-19 Pandemic. [published online ahead of print, 2021 Aug 9]. Open Forum Infect Dis. 2021. Doi: 10.1093/ofid/ofab417 Abdul-Mutakabbir JC, Casey S, Jews V, et al. A three-tiered approach to address barriers to COVID-19 vaccine delivery in the Black community. Lancet Glob Health. 2021 Jun;9(6):e749-e750. doi: 10.1016/S2214-109X(21)00099-1. Epub 2021 Mar 10. Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/

Featuring articles on salt substitution and cardiovascular events, safety of the BNT162b2 mRNA Covid-19 vaccine, lutetium-177 in prostate cancer, typhoid vaccine in Malawian children, and a call for emergency action on the climate crisis; a review article on the treatment of acute appendicitis; a case report of a woman with Covid-19 and suicidal ideation; and Perspective articles on public option plans and on the treatment of older adults with cancer.

American Thought Leaders- PART 2: Dr. Robert Malone on Ivermectin, Escape Mutants, and the Faulty Logic of Vaccine Mandates. AMERICAN THOUGHT LEADERS PART 2: Dr. Robert Malone on Ivermectin, Escape Mutants, and the Faulty Logic of Vaccine Mandates In part one of this American Thought Leaders episode, mRNA vaccine inventor Dr. Robert Malone explained the latest research on COVID-19 vaccines, booster shots, and natural immunity. Now in part two, we take a closer look at repurposed drugs like ivermectin and how a universal vaccination policy could actually backfire—and bring about the emergence of vaccine-resistant escape mutants. At their core, vaccine mandates are not just unethical and divisive, but also “impractical and unnecessary,” says Dr. Malone. You can watch the first part of this episode here. Below is a list of references mentioned or related to the discussion in this episode:  “Ivermectin for preventing and treating COVID-19” — The Cochrane Database of Systematic Reviews “Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019” — Chest Journal “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19” — American Journal of Therapeutics “Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial” — Clinical Therapeutics “Dexamethasone in Hospitalized Patients with Covid-19” — The New England Journal of Medicine “ACTIV-6: COVID-19 Study of Repurposed Medications” — NIH “Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals” — Cell Reports “Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization” — Nature The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines (Note: This is a preprint) “Mutation rate of COVID-19 virus is at least 50 percent higher than previously thought” — Phys.org “Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants” — The New England Journal of Medicine “Why is the ongoing mass vaccination experiment driving a rapid evolutionary response of SARS-CoV-2?” — Trial Site News “The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape” (Note: This is a preprint) “The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines” (Note: This is a preprint) “Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens” — PLOS Biology “Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant” (Note: This is a preprint). “Fauci: Amount of virus in breakthrough delta cases ‘almost identical' to unvaccinated” — The Hill CDC: “Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021” “Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California” (Note: This is a preprint) “New delta variant studies show the pandemic is far from over” — ScienceNews “Read: Internal CDC document on breakthrough infections” — The Washington Post “New UCSF study: Vaccine-resistant viruses are driving ‘breakthrough' COVID infections” — The Mercury News “Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections” (Note: This is a preprint) “Having SARS-CoV-2 once confers much greater immunity than a vaccine—but vaccination remains vital” — Science “Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals” (Note: This is a preprint) “SARS-CoV-2 variants of concern and variants under investigation in England” — Public Health England “Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting” — The New England Journal of Medicine “Real-World Study Captures Risk of Myocarditis With Pfizer Vax” — MedPage Today CDC: “Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020—August 2021” “CDC: Covid-19 Vaccine Effectiveness Fell From 91% To 66% With Delta Variant“ — Forbes “SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans” — Nature “Causes and consequences of purifying selection on SARS-CoV-2” — Genome Biology and Evolution “The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus” — Journal of Travel Medicine Subscribe to the American Thought Leaders newsletter so you never miss an episode. You can also follow American Thought Leaders on Parler, Facebook, or YouTube. If you'd like to donate to support our work, you can do so here. Follow Epoch TV on Facebook and Twitter. 

American Thought Leaders- PART 1. Dr. Robert Malone, mRNA Vaccine Inventor, on Latest COVID-19 Data AMERICAN THOUGHT LEADERS https://www.theepochtimes.com/c-american-thought-leaders  PART 1: Dr. Robert Malone, mRNA Vaccine Inventor, on Latest COVID-19 Data, Booster Shots, and the Shattered Scientific ‘Consensus' “We need to confront the data [and] not try to cover stuff up or hide risks,” says mRNA vaccine pioneer Dr. Robert Malone. What does the most recent research say about the efficacy of COVID-19 vaccines? In this two-part episode, we sit down again with Dr. Malone for a comprehensive look at the vaccines, booster shots, repurposed drugs like ivermectin, and the ethics of vaccine mandates. Jan Jekielek: Dr. Robert Malone, it's such a pleasure to have you back on American Thought Leaders. Dr. Robert Malone: Always my pleasure, Jan, and thank you for the chance to come back and visit. Mr. Jekielek: I want to read you a few headlines that I've come across in the last few weeks since we did our recent interview, and give you a chance to speak to them. This is a drophead: “Robert Malone claims to have invented mRNA technology. Why is he trying so hard to undermine its use?” How do you react to this? Dr. Malone: That's the Atlantic hit piece. It was a very interesting article because it has a number of logic jumps and irregularities. Then it ends up contradicting itself in the last paragraph, and basically confirming that my assertions about having being the originator of the core technology are valid. I'm subjected to this meme that you didn't really do the things that you did in the late 1980s almost continuously, usually from internet trolls.  So really what the young author was picking up on was some internet memes that have been wrapped around the prior press push that Katie Kariko and Drew Weissman were the ones that had originated the technology. Now that was clearly false, but it was very actively promoted by their university, which holds a key patent, and then advanced through Stat News, Boston Globe, CNN, and then finally the New York Times. We challenged that, and in the case of the New York Times, they actually recut their interview and podcast with Katie Kariko to cut out the parts where she had claimed that she was the original inventor.  But how do I react to it, this kind of pejorative use of language to cast shade? It doesn't really bother me. I know what the facts are, and I have this massive amount of documentation. When people come at me with those things, I just say, “Hey, look, here it's on the website. Here are the documents, you can make your own assessment.”  The thing that bothers me about all of this, when they're personalizing character assassination on me and character attacks, is that it distracts from the issues. And it's not about me, this kind of chronic questioning of why would I be saying things about the ethics of what's going on? Why would I be raising concerns about the safety signals? I must have some ulterior motive.  There's an underlying theme to all this, that I must have some ulterior motive. This particular journalist asked me again, and again, and again, trying to get at, “What was my ulterior motive for trying to undermine these vaccines based on my technology?” It was so paradoxical, the push of a whole series of questions that he raised with me.  I don't know what it says about journalism or what it says about our culture, that we always assume that someone must have an ulterior motive. It's not sufficient to just be addressing an issue because it matters, because it is the ethically correct thing to do. There seems to be this assumption that everybody's got an angle. It says more about the author than it says about me.  This kind of casting shade and aspersions on me personally as a way to avoid addressing the underlying issues, I just see it as a kind of noise and also a little bit sad. It's almost an affirmation. If the strongest thing they can come up with is to try to attack and cast shade on whether or not I made a significant contribution that led to over nine patents during the late 1980s—if that's the worst they can throw at me, I'm doing pretty good. So that's how I see it. Mr. Jekielek: So you're not trying, “So hard to undermine the use of this vaccine technology.” Dr. Malone: No. My concern here, as I said in our prior interview, is that there's been a series of actions taken, policies taken, regulatory actions taken, that are at odds with how I've been trained with the norms as I've always understood them. The regulatory norms, the scientific norms—these things have been waived. For a lot of people, it doesn't make sense.  And recall, reeling back, what triggered this was this amazing podcast with Bret Weinstein and Steve Kirsch, where I don't think at that point in time the world had really heard anyone questioning the underlying safety data assumptions and ethics of what was being done. There was a widespread sense of unease about these mandates and efforts to force vaccinations, and expedite the licensure of this and deploy it globally on the basis of very abbreviated clinical trials. There was a widespread sense of uneasiness.  But people didn't really have language to express it. When that podcast happened, for some reason, it catalyzed global interest in a way that I didn't expect. I still have people writing me, “I just saw the Bret Weinstein DarkHorse Podcast.” Something happened there, where events came together. I expressed some things that I had just been observing that I felt were anomalous in how the government was managing the situation, in the nature of the vaccines, in the testing of the vaccines, and in the ethics of how they were being deployed and forced on children, plus other things in various countries, including the United States.  That triggered a whole cascade, but it wasn't because I had concerns about the technology or was casting shade on the technology, I've repeatedly made it clear that, in my opinion, these vaccines have saved lives. I get challenged on that all the time, by the way. There's a whole cohort that says, “Oh no, these aren't worth anything. They shouldn't be used at all. They're not effective.”  In my opinion, they've saved a lot of lives and they're very appropriate at this point in time. The risk benefit favors administration of these vaccines, even with all we've learned since in these last few months, it favors their administration to the elderly and the high-risk populations. So contrary to this thread of I'm trying to denigrate these and tear them down—no, I'm trying to say I'm all in favor, strongly in favor of ethical development and deployment of vaccines that are safe, pure, effective, and non-adulterated.  I'm really strongly dug in that we need to confront the data as it is, and not try to cover stuff up or hide risks or avoid confronting risks. In my opinion, the way that we get to good public policy  in public health is we not only recognize those risks, but we also constantly take the position of looking forward, looking for leading indicators of risk, performing risk mitigation, and monitoring for black swans and unexpected events surrounding that. That's where I come from, strongly believing that the norms that have been developed over the last 30 to 40 years in vaccinology should be maintained. We shouldn't jettison them just because we're having a crisis. Mr. Jekielek: Why don't we do a review? There's been a number of very significant papers in the last week or two that have come out with very robust data sets telling us, to my less educated eye, some very valuable information. If you agree, maybe you can review some of these for us. I know you've been studying every one of these in some detail. Dr. Malone: The emergence of the Delta variant, whether originally in India and then subsequently in the UK and then in Israel, has really thrown back the public health enterprise globally and in these countries, because there were assumptions made about the effectiveness of the current vaccines and their ability to contain the outbreak. There was almost a social contract set up between the vaccine recipients and the governments and public health authorities. That social contract was, “Despite what you may have heard about the risks of some of these products and the fact that we admittedly did rush them, we're protecting your health. If you take these products, you will be safe.” That's the social contract. “Despite all these other concerns, you will be safe, and you won't have to retake them. You'll be protected.” People believed they had a shield if they bought in and did this. And then the Delta variant came along, and suddenly that was no longer valid. The assumption that had been made, the social contract, was somehow broken. First we found out, if you'll recall this cascade of events—we had Pfizer disclose that the durability, the length of time that the vaccine would provide protection was not as expected. It was something like six months. This came out of the Israeli data. Mr. Jekielek: Just to be clear, are we talking about protection from infection or protection from disease? Dr. Malone: That's a whole other rabbit hole. It really was protection from infection and spread that was the main parameter of concern with the six month data. You may recall that announcement was made unilaterally by Pfizer based on the Israeli data, and then immediately contradicted by Dr. Fauci saying that this wasn't true and Pfizer had no right to make these statements, and they hadn't discussed it with him. Pfizer then apologized and backed down.  And a week later, the U.S. government announced, that in fact, we were going to need to have boosters. Then there was the announcement that the government had contracted to buy the boosters that were going to be deployed at eight months. Then more data came out. Now most recently the government is saying, “We may have to have boosters at five months.” There was emergency use authorization that this third dose would be deployed to elderly and immunocompromised. And now we're talking about everybody needing it.  So this was the logic, “Take the dose, take the two shots or the one-shot for J&J and you'll be protected. We'll get out of this because we'll reach herd immunity. The whole problem is that we just don't have enough people that are being compliant with this.” Remember, this goes back to July 4th.  July 4th was the goal when we were going to have 70 per cent vaccine uptake. We didn't meet that. And there was a lot of discomfort with the Israeli data. Then all of this new information is rolled out, the Israeli data in particular, having to do with the increasing number of infections and hospitalizations.  At first the position was that this was only occurring in the unvaccinated cohort. Then that became increasingly untenable and it became clear that it was occurring in the vaccinated cohort. The same became true with the UK data set, which is stronger than the American monitoring system. They do a lot more sequence analysis.  So now we had this paradox that those that had been vaccinated, while the data still suggested that they're largely protected from disease and death and more protected than the unvaccinated from disease and death, they're no longer protected from infection. It became clear within the data, and through multiple sources, that the levels of virus replication in the individuals, even who had been vaccinated previously, was the same or higher as the levels of virus replication in those that had been un-vaccinated. And also that those that had been vaccinated and had breakthrough infections, which is what we're talking about, were also shedding virus and able to spread virus.  So that raised the prospect that they were kind of the new super spreaders, because they would have less apparent disease and yet still be shedding high levels of virus. Then we started to see some signs suggesting that there may be some differences in the nature or onset or titers of disease in those that had been infected beyond six months after their vaccination point. This is the waning phase.  That set up a situation where a lot of folks were on edge. There were still a lot of media pushing that this was a pandemic of the unvaccinated, but that became increasingly untenable as the data rolled in. You've referred to this paper that came out. There were actually three in a row that came out almost immediately after the license was issued for the BioNTech product.  There was a paper published in the New England Journal of Medicine that had an odd structure in which they related adverse events associated with the virus infection and a much more comprehensive assessment of adverse events associated with the vaccines. By juxtaposing these two data sets in the same manuscript, the case was made that, “Yes, we have this significantly enhanced spectrum of adverse events associated with the vaccine beyond what had been previously disclosed. We were all focused on the cardio-toxicity.”  But now, additional adverse events, and things that we discussed when we had our last chat as parent adverse events, these are now fairly well-documented in this New England Journal article, things like viral reactivation. So this is the shingles, for instance.  The paper attempts to make the case that, “The vaccines have a lot of adverse events, but the disease has a lot of adverse events also, and the disease is worse. Also there's a lot of overlap between these adverse events associated with the disease and the vaccine.” But the messaging was focused in that manuscript that it was far worse to get the disease than to have the adverse events associated with the vaccine.  That's a little bit of a false analogy, because the vaccine ostensibly would be deployed to 80 or 90 per cent of the population. And in terms of this wave of Delta, we might see something like 20 or 30 per cent of the population infected if we're lucky. Then there's an imbalance of who's at risk with the vaccine versus who's at risk for the infection, but that was the construct. Mr. Jekielek: And just to be clear, what do you mean by 20 to 30 per cent, if we're lucky? Where do those numbers come from? Dr. Malone: I've seen data suggesting that the total population right now that's been infected in the United States is something like about 20 per cent of the total population. We don't have that widespread of an uptake of infection in the U.S. or in the UK. UK data also shows those kinds of numbers. They're reflected in a cohort that have had a natural infection and recovered from that, and then acquired the immune response associated with that.  It's seen in the numbers, for instance, in those cases where there is an accounting, such as in the Great Britain database, the British database, where they say the fraction of the population that's been vaccinated, and then the fraction of the population that's acquired natural immunity. It's also covered in the CDC slide deck that was leaked. I don't think that was available when we had our last conversation.  At the early outset, at the front edge of the Delta outbreak here in the United States, there was a key slide deck that was disclosed to the Washington Post without approval by a CDC employee. Within that slide deck, it showed a number of confidential internal assessments that weren't intended to be shared with the public. Those assessments also included an estimate that we had something like 50 per cent of the population that had accepted vaccine at that point in time. In addition, there was something like 20 per cent of the population that had been infected.  So if you add those two, if you were to consider natural infection as providing some degree of protection against the virus, then we would move from something like 50 per cent vaccine uptake to something like 70 per cent of the population at that point in time that had actually acquired some form of immunity either through vaccination or infection. So that's the basis of my seat-of-the-pants estimate.  In addition, in the CDC slide deck, the government revealed in two key slides that were at the center of that deck, that their epidemiologic calculations and projections were such that the reproductive coefficient of Delta was something in the range of eight. There's other papers that suggest it's more like a little over five, that it was as infectious as chickenpox approximately, which is highly infectious, about two to three times more infectious than the Alpha strain was.  Based on those projections and some assumptions about the percent of the population that had been naturally infected, and the percent of the population that had taken up vaccine, and some assumptions about the effectiveness of mask use in protecting either an individual from being infected by a third party that wasn't using masks or protecting a third party from infection from somebody that was using a mask and was infected—there were a series of projection curves about how that could impact on the spread of the virus.  Basically when you work through those curves, what they demonstrated was that even if we had 100 per cent vaccine uptake with these vaccines, where the technical term is leaky, that do not provide perfect protection against infection, that we would not be able to stop the spread of the virus through the U.S. population. We would slow it. So that's where those estimates come from.  That's where that assessment that is being used as the basis for advocating widespread mask deployment throughout the United States, that's where that policy comes from. It's a CDC analysis that if we don't use masks, then the virus will spread quite rapidly. If we do have full compliance with mask use, we can slow it down a bit. And so that's why we have these various mask mandates throughout the United States now. Mr. Jekielek: Fascinating. You started talking about natural immunity here. I thought it was some of the most interesting, robust data, at least to my eye. Again, you're the one who's going to be speaking on this. Dr. Malone: I agree, and a lot of people agree. It was covered in Science magazine. It's still a pre-print, but it was robust enough, and well enough constructed that even on the basis of the pre-print, Science magazine went ahead and made the clear point. Really, throughout the world, there was recognition that this new data coming out of Israel, as I recall, demonstrated that the term that's often used is natural immunity. It's an odd term, but it's now in common language.  What that means is protection afforded by having been infected and recovered from infection, which will generate a broad immune response. And it's now been shown in that paper and others that the breadth of that immune response in terms of memory T and B cell populations is more diverse and more long lasting than the breadth of immune response elicited by the spike based vaccines alone.  That data that you're alluding to showed that this natural immunity is broader and more durable, which contradicted some studies that the CDC had developed. So we were in a kind of tension. Which is the real data, the CDC data, or these other papers that are evaluated memory T and B cell populations? Which is true? We have multiple truths or multiple pieces of data, plus different groups claiming it's one way or the other.  Then this data was dropped about the evidence of protection. It seems to indicate and be consistent with the claims that the breadth and durability of the immune response was superior with the natural infection in recovery. There's also evidence that there's a significant, depending on the timeframe, six to twenty-fold improvement in protection from infection and disease associated with the natural immunity acquired from prior infection, compared to that conferred by the vaccine.  So now the public, in their social contract with the public health agencies, is faced with the situation where they had been told that natural immunity was not as protective, and that they can't rely on that. If you've been previously infected, you should still get both doses of vaccine, and this vaccination would provide broad, durable protection. It would protect you, and it would protect your elders from you potentially spreading disease to them.  Now, those things have all come into question. The population is still reeling from that. We have kind of dug into these camps. My sense is that people haven't really fully processed what this means. It is profound.  We were discussing before we started shooting, that I had a long podcast interview today and a kind of advisory session with a group of Latin American physicians and scientists that were evaluating public policy for vaccine rollout versus early treatment options for the different cohorts that they have to protect. They were seeing this data from the eyes of folks that really haven't had good access to vaccines, but are facing the prospects that their countries could execute vaccine contracts and bring in these vaccines. They are asking the question, “Does this make sense for us? Is this good policy? Should our country invest in these mRNA vaccines?”  That is why they were talking to me. “What are we going to get for it if we do this? What's going to be the benefit to our population?” It was a very level-headed discussion. But they were pushing me in this, getting back to this theme of me being the vaccine skeptic. They were the ones pushing me saying, “We just don't see the value here for our populations. We don't see a compelling case when these products aren't stopping the spread. They are going to have to be re-administered fairly frequently if they're to be effective?”  Now, the other thing that comes out of this, a concern that the World Health Organization hasn't really come to terms with—I'm speaking of the CDC and the WHO and the whole global infrastructure, including the Israeli government—is one of now mandating a third jab. So in Israel, if you haven't received all three, you're not considered fully vaccinated. Mr. Jekielek: You have a six month window, if I'm not mistaken. Dr. Malone: Precisely. But one of the things about the Israeli data is that they vaccinated in such a bolus, in such a short push, because they have such a compliant population, that essentially, they have a spike in vaccinated persons. So they're all moving concurrently through that six month window now.  There was a pivotal interview with the director of the CDC and she was asked, “Do we have any data? Do we have data, or do we just have hope about the benefits of the third dose?” And she, to her credit, acknowledged that we don't have data. All we have is hope.  Here's the problem with that. Vaccine responses are not linear. More is not better. There are many cases where if you dose more or dose more frequently or move beyond a prime and a boost, you can actually quench the immune response. You can move into “high zone tolerance.” You can move into a situation where your immune responses drop.  Now there's a little bit of foreshadowing on this in another paper that's out where they looked at the effects of vaccination post-infection. Remember this was the policy, that those like me that have been infected should go ahead and take two jabs, take two doses of vaccine. Mr. Jekielek: Which you did. Dr. Malone: Which I did, hoping that it would be helpful for a long COVID period. That data hasn't really played out that way. And there's a paper showing that you can actually quench T-cell responses. You get an improved kind of a super immune response, they assert in that manuscript, after a single dose when you've been previously infected. But with the second dose, your T-cell population actually gets quenched, which is consistent with high zone tolerance.  So if that paper was to be expanded and verified with more robust numbers, it would suggest that one dose after natural infection would be a good thing. Two doses would be a bad thing. Now that's the equivalent of three doses if you think about it, natural infection being dose one. So to say that we don't have any data is a little misleading. We have some leading indicators that suggest that it might not be such a good idea. And now, that data will come out from Israel. The conservative position to take is time will tell, and then we will know.  The Israelis continue to be in the throes of a very active Delta virus infection surge right now. There's some other very intriguing tidbits going on here in this whole public policy of vaccines versus no vaccines, versus universal vaccines, versus the Barrington position that we should selectively vaccinate those that are at high risk. Mr. Jekielek: The Great Barrington Declaration? Dr. Malone: Yes, the Great Barrington Declaration. After that whole matrix of decisions, in comes Sweden. You may recall that Sweden was roundly criticized for this naive notion that they weren't going to vaccinate. They were going to allow the virus to have its will with the population. They have backtracked from that now, to be technically accurate. They have about 40 per cent vaccine uptake and they've acknowledged that position was naive and counterproductive. They had excess deaths initially in the high-risk cohorts.  But what they did do was have a lot more natural infection with alpha and beta strains. And now that Delta is moving through the region, they have an extremely low mortality rate, often hitting zero on any one day—in comparison to some of their neighbors that didn't take that policy, and didn't have such widespread natural infection. Like Finland, for example, where they deployed vaccine very avidly and had good uptake, they're having the exponential growth rate curve that's happening in many other Northern European countries right now. Mr. Jekielek: I'm going to comment here. This is very interesting because you're interpreting this data a bit differently than Dr. Martin Kulldorff, who is from Sweden.  His commentary in a recent interview we did was simply that there were no mandates of any sort ever in Sweden, yet their vaccine use is actually quite high. He said it's one of the higher rates that exist. But he didn't factor in this time period that you said at the beginning, where there was this idea of letting the natural infections happen. And you're saying the reason their rates are zero mortality is because of that. Dr. Malone: Yes. It is a very reasonable explanation for what's happened there. It's a differentiator between them and some of their neighboring countries. They did have that early policy and they did have fairly widespread infection. So that would be consistent with the data suggesting that natural infection is providing broader and more durable immunity.  This gets to the logic of a selective deployment of vaccines to those that are at highest risk. For that fragment of the population, let's say below 65, depending on where you want to cut the line, 60, 65, 70, some people go down to 55, not providing vaccine coverage to those individuals unless they're in a very high risk population, morbidly obese, or with immunologic deficiencies—that may be a more enlightened public policy.  By the way, it is one more consistent with the WHO position that we still have limited vaccine supply, and it would be far more appropriate and equitable to deploy that vaccine supply more broadly globally to protect the elders in particular throughout the world, rather than this focus on universal vaccination.  Now with a booster, a third booster, a third dose, there's been multiple statements by the WHO that they believe this is not ethical. Now, I had another interview today with a journalist podcaster who is from South Africa but living in France, and very aware of the French resistance that's developing now to vaccines with all those protests. Mr. Jekielek: To vaccine mandates, correct? Dr. Malone: In particular, yes. His point was that if you look at this through the eyes of emerging economies, this Western focus on universal vaccination of their populations and now a third vaccine for their populations and their unwillingness to share the technology is a form of imperialism and hegemony. The Western nations have access to this technology and these doses and they're not willing to share it with the rest of the world.  So we've got a series of things here where this kind of imbalance in distribution of these vaccines as a resource is creating or exacerbating concerns that exist widely in economically disadvantaged countries. There's just not a level playing field and we're all in this boat together with this disease. Yet we're not being equitable in distribution of the countermeasures that are available. Mr. Jekielek: This is fascinating, even as others that you're speaking with are asking, “Do we even need these at this point?” That's fascinating. Dr. Malone: Yes, I agree. So what does this mean? I don't know. What I sense is, again, we're in one of those moments where there is chaos. There's lack of structure and consensus about how to move forward. And my sense is, getting back to the U.S. government, we're in a position now where a lot of the core assumptions underlying the vaccine strategy have been called into question. We don't really know what's on the other side.  Then on top of that, it's becoming increasingly apparent that these repurposed drugs and other agents that could provide protection and mitigate death and disease, if they were deployed early in outpatient environments, access to those that are being actively suppressed. That's another one of those, “This doesn't make sense,” kind of problems. It is causing a lot of questioning about the motivations of those that are guiding public policy right now. The second part of this episode will be released on Saturday, Sept. 4, at 7 p.m. ET. Below is a list of references mentioned or related to the discussion in this episode:  “Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant” (Note: This is a preprint). “Fauci: Amount of virus in breakthrough delta cases ‘almost identical' to unvaccinated” — The Hill CDC: “Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021” “Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California” (Note: This is a preprint) “New delta variant studies show the pandemic is far from over” — ScienceNews “Read: Internal CDC document on breakthrough infections” — The Washington Post “New UCSF study: Vaccine-resistant viruses are driving ‘breakthrough' COVID infections” — The Mercury News “Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections” (Note: This is a preprint) “Having SARS-CoV-2 once confers much greater immunity than a vaccine—but vaccination remains vital” — Science “Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals” (Note: This is a preprint) “SARS-CoV-2 variants of concern and variants under investigation in England” — Public Health England “Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting” — The New England Journal of Medicine “Real-World Study Captures Risk of Myocarditis With Pfizer Vax” — MedPage Today CDC: “Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020—August 2021” “CDC: Covid-19 Vaccine Effectiveness Fell From 91% To 66% With Delta Variant“ — Forbes “SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans” — Nature CDC: “Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May-June 2021” “Causes and consequences of purifying selection on SARS-CoV-2” — Genome Biology and Evolution “The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus” — Journal of Travel Medicine “Mutation rate of COVID-19 virus is at least 50 percent higher than previously thought” — Phys.org “Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals” (Note: This is a preprint) Subscribe to the American Thought Leaders newsletter so you never miss an episode. You can also follow American Thought Leaders on Parler, Facebook, or YouTube. If you'd like to donate to support our work, you can do so here. Follow Epoch TV on Facebook and Twitter. 

American Thought Leaders- PART 2: Dr. Robert Malone on Ivermectin, Escape Mutants, and the Faulty Logic of Vaccine Mandates. AMERICAN THOUGHT LEADERS PART 2: Dr. Robert Malone on Ivermectin, Escape Mutants, and the Faulty Logic of Vaccine Mandates In part one of this American Thought Leaders episode, mRNA vaccine inventor Dr. Robert Malone explained the latest research on COVID-19 vaccines, booster shots, and natural immunity. Now in part two, we take a closer look at repurposed drugs like ivermectin and how a universal vaccination policy could actually backfire—and bring about the emergence of vaccine-resistant escape mutants. At their core, vaccine mandates are not just unethical and divisive, but also “impractical and unnecessary,” says Dr. Malone. You can watch the first part of this episode here. Below is a list of references mentioned or related to the discussion in this episode:  “Ivermectin for preventing and treating COVID-19” — The Cochrane Database of Systematic Reviews “Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019” — Chest Journal “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19” — American Journal of Therapeutics “Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial” — Clinical Therapeutics “Dexamethasone in Hospitalized Patients with Covid-19” — The New England Journal of Medicine “ACTIV-6: COVID-19 Study of Repurposed Medications” — NIH “Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals” — Cell Reports “Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization” — Nature The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines (Note: This is a preprint) “Mutation rate of COVID-19 virus is at least 50 percent higher than previously thought” — Phys.org “Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants” — The New England Journal of Medicine “Why is the ongoing mass vaccination experiment driving a rapid evolutionary response of SARS-CoV-2?” — Trial Site News “The emergence and ongoing convergent evolution of the N501Y lineages coincides with a major global shift in the SARS-CoV-2 selective landscape” (Note: This is a preprint) “The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines” (Note: This is a preprint) “Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens” — PLOS Biology “Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant” (Note: This is a preprint). “Fauci: Amount of virus in breakthrough delta cases ‘almost identical' to unvaccinated” — The Hill CDC: “Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021” “Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California” (Note: This is a preprint) “New delta variant studies show the pandemic is far from over” — ScienceNews “Read: Internal CDC document on breakthrough infections” — The Washington Post “New UCSF study: Vaccine-resistant viruses are driving ‘breakthrough' COVID infections” — The Mercury News “Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections” (Note: This is a preprint) “Having SARS-CoV-2 once confers much greater immunity than a vaccine—but vaccination remains vital” — Science “Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals” (Note: This is a preprint) “SARS-CoV-2 variants of concern and variants under investigation in England” — Public Health England “Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting” — The New England Journal of Medicine “Real-World Study Captures Risk of Myocarditis With Pfizer Vax” — MedPage Today CDC: “Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020—August 2021” “CDC: Covid-19 Vaccine Effectiveness Fell From 91% To 66% With Delta Variant“ — Forbes “SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans” — Nature “Causes and consequences of purifying selection on SARS-CoV-2” — Genome Biology and Evolution “The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus” — Journal of Travel Medicine Subscribe to the American Thought Leaders newsletter so you never miss an episode. You can also follow American Thought Leaders on Parler, Facebook, or YouTube. If you'd like to donate to support our work, you can do so here. Follow Epoch TV on Facebook and Twitter. 

American Thought Leaders- PART 1. Dr. Robert Malone, mRNA Vaccine Inventor, on Latest COVID-19 Data AMERICAN THOUGHT LEADERS https://www.theepochtimes.com/c-american-thought-leaders  PART 1: Dr. Robert Malone, mRNA Vaccine Inventor, on Latest COVID-19 Data, Booster Shots, and the Shattered Scientific ‘Consensus' “We need to confront the data [and] not try to cover stuff up or hide risks,” says mRNA vaccine pioneer Dr. Robert Malone. What does the most recent research say about the efficacy of COVID-19 vaccines? In this two-part episode, we sit down again with Dr. Malone for a comprehensive look at the vaccines, booster shots, repurposed drugs like ivermectin, and the ethics of vaccine mandates. Jan Jekielek: Dr. Robert Malone, it's such a pleasure to have you back on American Thought Leaders. Dr. Robert Malone: Always my pleasure, Jan, and thank you for the chance to come back and visit. Mr. Jekielek: I want to read you a few headlines that I've come across in the last few weeks since we did our recent interview, and give you a chance to speak to them. This is a drophead: “Robert Malone claims to have invented mRNA technology. Why is he trying so hard to undermine its use?” How do you react to this? Dr. Malone: That's the Atlantic hit piece. It was a very interesting article because it has a number of logic jumps and irregularities. Then it ends up contradicting itself in the last paragraph, and basically confirming that my assertions about having being the originator of the core technology are valid. I'm subjected to this meme that you didn't really do the things that you did in the late 1980s almost continuously, usually from internet trolls.  So really what the young author was picking up on was some internet memes that have been wrapped around the prior press push that Katie Kariko and Drew Weissman were the ones that had originated the technology. Now that was clearly false, but it was very actively promoted by their university, which holds a key patent, and then advanced through Stat News, Boston Globe, CNN, and then finally the New York Times. We challenged that, and in the case of the New York Times, they actually recut their interview and podcast with Katie Kariko to cut out the parts where she had claimed that she was the original inventor.  But how do I react to it, this kind of pejorative use of language to cast shade? It doesn't really bother me. I know what the facts are, and I have this massive amount of documentation. When people come at me with those things, I just say, “Hey, look, here it's on the website. Here are the documents, you can make your own assessment.”  The thing that bothers me about all of this, when they're personalizing character assassination on me and character attacks, is that it distracts from the issues. And it's not about me, this kind of chronic questioning of why would I be saying things about the ethics of what's going on? Why would I be raising concerns about the safety signals? I must have some ulterior motive.  There's an underlying theme to all this, that I must have some ulterior motive. This particular journalist asked me again, and again, and again, trying to get at, “What was my ulterior motive for trying to undermine these vaccines based on my technology?” It was so paradoxical, the push of a whole series of questions that he raised with me.  I don't know what it says about journalism or what it says about our culture, that we always assume that someone must have an ulterior motive. It's not sufficient to just be addressing an issue because it matters, because it is the ethically correct thing to do. There seems to be this assumption that everybody's got an angle. It says more about the author than it says about me.  This kind of casting shade and aspersions on me personally as a way to avoid addressing the underlying issues, I just see it as a kind of noise and also a little bit sad. It's almost an affirmation. If the strongest thing they can come up with is to try to attack and cast shade on whether or not I made a significant contribution that led to over nine patents during the late 1980s—if that's the worst they can throw at me, I'm doing pretty good. So that's how I see it. Mr. Jekielek: So you're not trying, “So hard to undermine the use of this vaccine technology.” Dr. Malone: No. My concern here, as I said in our prior interview, is that there's been a series of actions taken, policies taken, regulatory actions taken, that are at odds with how I've been trained with the norms as I've always understood them. The regulatory norms, the scientific norms—these things have been waived. For a lot of people, it doesn't make sense.  And recall, reeling back, what triggered this was this amazing podcast with Bret Weinstein and Steve Kirsch, where I don't think at that point in time the world had really heard anyone questioning the underlying safety data assumptions and ethics of what was being done. There was a widespread sense of unease about these mandates and efforts to force vaccinations, and expedite the licensure of this and deploy it globally on the basis of very abbreviated clinical trials. There was a widespread sense of uneasiness.  But people didn't really have language to express it. When that podcast happened, for some reason, it catalyzed global interest in a way that I didn't expect. I still have people writing me, “I just saw the Bret Weinstein DarkHorse Podcast.” Something happened there, where events came together. I expressed some things that I had just been observing that I felt were anomalous in how the government was managing the situation, in the nature of the vaccines, in the testing of the vaccines, and in the ethics of how they were being deployed and forced on children, plus other things in various countries, including the United States.  That triggered a whole cascade, but it wasn't because I had concerns about the technology or was casting shade on the technology, I've repeatedly made it clear that, in my opinion, these vaccines have saved lives. I get challenged on that all the time, by the way. There's a whole cohort that says, “Oh no, these aren't worth anything. They shouldn't be used at all. They're not effective.”  In my opinion, they've saved a lot of lives and they're very appropriate at this point in time. The risk benefit favors administration of these vaccines, even with all we've learned since in these last few months, it favors their administration to the elderly and the high-risk populations. So contrary to this thread of I'm trying to denigrate these and tear them down—no, I'm trying to say I'm all in favor, strongly in favor of ethical development and deployment of vaccines that are safe, pure, effective, and non-adulterated.  I'm really strongly dug in that we need to confront the data as it is, and not try to cover stuff up or hide risks or avoid confronting risks. In my opinion, the way that we get to good public policy  in public health is we not only recognize those risks, but we also constantly take the position of looking forward, looking for leading indicators of risk, performing risk mitigation, and monitoring for black swans and unexpected events surrounding that. That's where I come from, strongly believing that the norms that have been developed over the last 30 to 40 years in vaccinology should be maintained. We shouldn't jettison them just because we're having a crisis. Mr. Jekielek: Why don't we do a review? There's been a number of very significant papers in the last week or two that have come out with very robust data sets telling us, to my less educated eye, some very valuable information. If you agree, maybe you can review some of these for us. I know you've been studying every one of these in some detail. Dr. Malone: The emergence of the Delta variant, whether originally in India and then subsequently in the UK and then in Israel, has really thrown back the public health enterprise globally and in these countries, because there were assumptions made about the effectiveness of the current vaccines and their ability to contain the outbreak. There was almost a social contract set up between the vaccine recipients and the governments and public health authorities. That social contract was, “Despite what you may have heard about the risks of some of these products and the fact that we admittedly did rush them, we're protecting your health. If you take these products, you will be safe.” That's the social contract. “Despite all these other concerns, you will be safe, and you won't have to retake them. You'll be protected.” People believed they had a shield if they bought in and did this. And then the Delta variant came along, and suddenly that was no longer valid. The assumption that had been made, the social contract, was somehow broken. First we found out, if you'll recall this cascade of events—we had Pfizer disclose that the durability, the length of time that the vaccine would provide protection was not as expected. It was something like six months. This came out of the Israeli data. Mr. Jekielek: Just to be clear, are we talking about protection from infection or protection from disease? Dr. Malone: That's a whole other rabbit hole. It really was protection from infection and spread that was the main parameter of concern with the six month data. You may recall that announcement was made unilaterally by Pfizer based on the Israeli data, and then immediately contradicted by Dr. Fauci saying that this wasn't true and Pfizer had no right to make these statements, and they hadn't discussed it with him. Pfizer then apologized and backed down.  And a week later, the U.S. government announced, that in fact, we were going to need to have boosters. Then there was the announcement that the government had contracted to buy the boosters that were going to be deployed at eight months. Then more data came out. Now most recently the government is saying, “We may have to have boosters at five months.” There was emergency use authorization that this third dose would be deployed to elderly and immunocompromised. And now we're talking about everybody needing it.  So this was the logic, “Take the dose, take the two shots or the one-shot for J&J and you'll be protected. We'll get out of this because we'll reach herd immunity. The whole problem is that we just don't have enough people that are being compliant with this.” Remember, this goes back to July 4th.  July 4th was the goal when we were going to have 70 per cent vaccine uptake. We didn't meet that. And there was a lot of discomfort with the Israeli data. Then all of this new information is rolled out, the Israeli data in particular, having to do with the increasing number of infections and hospitalizations.  At first the position was that this was only occurring in the unvaccinated cohort. Then that became increasingly untenable and it became clear that it was occurring in the vaccinated cohort. The same became true with the UK data set, which is stronger than the American monitoring system. They do a lot more sequence analysis.  So now we had this paradox that those that had been vaccinated, while the data still suggested that they're largely protected from disease and death and more protected than the unvaccinated from disease and death, they're no longer protected from infection. It became clear within the data, and through multiple sources, that the levels of virus replication in the individuals, even who had been vaccinated previously, was the same or higher as the levels of virus replication in those that had been un-vaccinated. And also that those that had been vaccinated and had breakthrough infections, which is what we're talking about, were also shedding virus and able to spread virus.  So that raised the prospect that they were kind of the new super spreaders, because they would have less apparent disease and yet still be shedding high levels of virus. Then we started to see some signs suggesting that there may be some differences in the nature or onset or titers of disease in those that had been infected beyond six months after their vaccination point. This is the waning phase.  That set up a situation where a lot of folks were on edge. There were still a lot of media pushing that this was a pandemic of the unvaccinated, but that became increasingly untenable as the data rolled in. You've referred to this paper that came out. There were actually three in a row that came out almost immediately after the license was issued for the BioNTech product.  There was a paper published in the New England Journal of Medicine that had an odd structure in which they related adverse events associated with the virus infection and a much more comprehensive assessment of adverse events associated with the vaccines. By juxtaposing these two data sets in the same manuscript, the case was made that, “Yes, we have this significantly enhanced spectrum of adverse events associated with the vaccine beyond what had been previously disclosed. We were all focused on the cardio-toxicity.”  But now, additional adverse events, and things that we discussed when we had our last chat as parent adverse events, these are now fairly well-documented in this New England Journal article, things like viral reactivation. So this is the shingles, for instance.  The paper attempts to make the case that, “The vaccines have a lot of adverse events, but the disease has a lot of adverse events also, and the disease is worse. Also there's a lot of overlap between these adverse events associated with the disease and the vaccine.” But the messaging was focused in that manuscript that it was far worse to get the disease than to have the adverse events associated with the vaccine.  That's a little bit of a false analogy, because the vaccine ostensibly would be deployed to 80 or 90 per cent of the population. And in terms of this wave of Delta, we might see something like 20 or 30 per cent of the population infected if we're lucky. Then there's an imbalance of who's at risk with the vaccine versus who's at risk for the infection, but that was the construct. Mr. Jekielek: And just to be clear, what do you mean by 20 to 30 per cent, if we're lucky? Where do those numbers come from? Dr. Malone: I've seen data suggesting that the total population right now that's been infected in the United States is something like about 20 per cent of the total population. We don't have that widespread of an uptake of infection in the U.S. or in the UK. UK data also shows those kinds of numbers. They're reflected in a cohort that have had a natural infection and recovered from that, and then acquired the immune response associated with that.  It's seen in the numbers, for instance, in those cases where there is an accounting, such as in the Great Britain database, the British database, where they say the fraction of the population that's been vaccinated, and then the fraction of the population that's acquired natural immunity. It's also covered in the CDC slide deck that was leaked. I don't think that was available when we had our last conversation.  At the early outset, at the front edge of the Delta outbreak here in the United States, there was a key slide deck that was disclosed to the Washington Post without approval by a CDC employee. Within that slide deck, it showed a number of confidential internal assessments that weren't intended to be shared with the public. Those assessments also included an estimate that we had something like 50 per cent of the population that had accepted vaccine at that point in time. In addition, there was something like 20 per cent of the population that had been infected.  So if you add those two, if you were to consider natural infection as providing some degree of protection against the virus, then we would move from something like 50 per cent vaccine uptake to something like 70 per cent of the population at that point in time that had actually acquired some form of immunity either through vaccination or infection. So that's the basis of my seat-of-the-pants estimate.  In addition, in the CDC slide deck, the government revealed in two key slides that were at the center of that deck, that their epidemiologic calculations and projections were such that the reproductive coefficient of Delta was something in the range of eight. There's other papers that suggest it's more like a little over five, that it was as infectious as chickenpox approximately, which is highly infectious, about two to three times more infectious than the Alpha strain was.  Based on those projections and some assumptions about the percent of the population that had been naturally infected, and the percent of the population that had taken up vaccine, and some assumptions about the effectiveness of mask use in protecting either an individual from being infected by a third party that wasn't using masks or protecting a third party from infection from somebody that was using a mask and was infected—there were a series of projection curves about how that could impact on the spread of the virus.  Basically when you work through those curves, what they demonstrated was that even if we had 100 per cent vaccine uptake with these vaccines, where the technical term is leaky, that do not provide perfect protection against infection, that we would not be able to stop the spread of the virus through the U.S. population. We would slow it. So that's where those estimates come from.  That's where that assessment that is being used as the basis for advocating widespread mask deployment throughout the United States, that's where that policy comes from. It's a CDC analysis that if we don't use masks, then the virus will spread quite rapidly. If we do have full compliance with mask use, we can slow it down a bit. And so that's why we have these various mask mandates throughout the United States now. Mr. Jekielek: Fascinating. You started talking about natural immunity here. I thought it was some of the most interesting, robust data, at least to my eye. Again, you're the one who's going to be speaking on this. Dr. Malone: I agree, and a lot of people agree. It was covered in Science magazine. It's still a pre-print, but it was robust enough, and well enough constructed that even on the basis of the pre-print, Science magazine went ahead and made the clear point. Really, throughout the world, there was recognition that this new data coming out of Israel, as I recall, demonstrated that the term that's often used is natural immunity. It's an odd term, but it's now in common language.  What that means is protection afforded by having been infected and recovered from infection, which will generate a broad immune response. And it's now been shown in that paper and others that the breadth of that immune response in terms of memory T and B cell populations is more diverse and more long lasting than the breadth of immune response elicited by the spike based vaccines alone.  That data that you're alluding to showed that this natural immunity is broader and more durable, which contradicted some studies that the CDC had developed. So we were in a kind of tension. Which is the real data, the CDC data, or these other papers that are evaluated memory T and B cell populations? Which is true? We have multiple truths or multiple pieces of data, plus different groups claiming it's one way or the other.  Then this data was dropped about the evidence of protection. It seems to indicate and be consistent with the claims that the breadth and durability of the immune response was superior with the natural infection in recovery. There's also evidence that there's a significant, depending on the timeframe, six to twenty-fold improvement in protection from infection and disease associated with the natural immunity acquired from prior infection, compared to that conferred by the vaccine.  So now the public, in their social contract with the public health agencies, is faced with the situation where they had been told that natural immunity was not as protective, and that they can't rely on that. If you've been previously infected, you should still get both doses of vaccine, and this vaccination would provide broad, durable protection. It would protect you, and it would protect your elders from you potentially spreading disease to them.  Now, those things have all come into question. The population is still reeling from that. We have kind of dug into these camps. My sense is that people haven't really fully processed what this means. It is profound.  We were discussing before we started shooting, that I had a long podcast interview today and a kind of advisory session with a group of Latin American physicians and scientists that were evaluating public policy for vaccine rollout versus early treatment options for the different cohorts that they have to protect. They were seeing this data from the eyes of folks that really haven't had good access to vaccines, but are facing the prospects that their countries could execute vaccine contracts and bring in these vaccines. They are asking the question, “Does this make sense for us? Is this good policy? Should our country invest in these mRNA vaccines?”  That is why they were talking to me. “What are we going to get for it if we do this? What's going to be the benefit to our population?” It was a very level-headed discussion. But they were pushing me in this, getting back to this theme of me being the vaccine skeptic. They were the ones pushing me saying, “We just don't see the value here for our populations. We don't see a compelling case when these products aren't stopping the spread. They are going to have to be re-administered fairly frequently if they're to be effective?”  Now, the other thing that comes out of this, a concern that the World Health Organization hasn't really come to terms with—I'm speaking of the CDC and the WHO and the whole global infrastructure, including the Israeli government—is one of now mandating a third jab. So in Israel, if you haven't received all three, you're not considered fully vaccinated. Mr. Jekielek: You have a six month window, if I'm not mistaken. Dr. Malone: Precisely. But one of the things about the Israeli data is that they vaccinated in such a bolus, in such a short push, because they have such a compliant population, that essentially, they have a spike in vaccinated persons. So they're all moving concurrently through that six month window now.  There was a pivotal interview with the director of the CDC and she was asked, “Do we have any data? Do we have data, or do we just have hope about the benefits of the third dose?” And she, to her credit, acknowledged that we don't have data. All we have is hope.  Here's the problem with that. Vaccine responses are not linear. More is not better. There are many cases where if you dose more or dose more frequently or move beyond a prime and a boost, you can actually quench the immune response. You can move into “high zone tolerance.” You can move into a situation where your immune responses drop.  Now there's a little bit of foreshadowing on this in another paper that's out where they looked at the effects of vaccination post-infection. Remember this was the policy, that those like me that have been infected should go ahead and take two jabs, take two doses of vaccine. Mr. Jekielek: Which you did. Dr. Malone: Which I did, hoping that it would be helpful for a long COVID period. That data hasn't really played out that way. And there's a paper showing that you can actually quench T-cell responses. You get an improved kind of a super immune response, they assert in that manuscript, after a single dose when you've been previously infected. But with the second dose, your T-cell population actually gets quenched, which is consistent with high zone tolerance.  So if that paper was to be expanded and verified with more robust numbers, it would suggest that one dose after natural infection would be a good thing. Two doses would be a bad thing. Now that's the equivalent of three doses if you think about it, natural infection being dose one. So to say that we don't have any data is a little misleading. We have some leading indicators that suggest that it might not be such a good idea. And now, that data will come out from Israel. The conservative position to take is time will tell, and then we will know.  The Israelis continue to be in the throes of a very active Delta virus infection surge right now. There's some other very intriguing tidbits going on here in this whole public policy of vaccines versus no vaccines, versus universal vaccines, versus the Barrington position that we should selectively vaccinate those that are at high risk. Mr. Jekielek: The Great Barrington Declaration? Dr. Malone: Yes, the Great Barrington Declaration. After that whole matrix of decisions, in comes Sweden. You may recall that Sweden was roundly criticized for this naive notion that they weren't going to vaccinate. They were going to allow the virus to have its will with the population. They have backtracked from that now, to be technically accurate. They have about 40 per cent vaccine uptake and they've acknowledged that position was naive and counterproductive. They had excess deaths initially in the high-risk cohorts.  But what they did do was have a lot more natural infection with alpha and beta strains. And now that Delta is moving through the region, they have an extremely low mortality rate, often hitting zero on any one day—in comparison to some of their neighbors that didn't take that policy, and didn't have such widespread natural infection. Like Finland, for example, where they deployed vaccine very avidly and had good uptake, they're having the exponential growth rate curve that's happening in many other Northern European countries right now. Mr. Jekielek: I'm going to comment here. This is very interesting because you're interpreting this data a bit differently than Dr. Martin Kulldorff, who is from Sweden.  His commentary in a recent interview we did was simply that there were no mandates of any sort ever in Sweden, yet their vaccine use is actually quite high. He said it's one of the higher rates that exist. But he didn't factor in this time period that you said at the beginning, where there was this idea of letting the natural infections happen. And you're saying the reason their rates are zero mortality is because of that. Dr. Malone: Yes. It is a very reasonable explanation for what's happened there. It's a differentiator between them and some of their neighboring countries. They did have that early policy and they did have fairly widespread infection. So that would be consistent with the data suggesting that natural infection is providing broader and more durable immunity.  This gets to the logic of a selective deployment of vaccines to those that are at highest risk. For that fragment of the population, let's say below 65, depending on where you want to cut the line, 60, 65, 70, some people go down to 55, not providing vaccine coverage to those individuals unless they're in a very high risk population, morbidly obese, or with immunologic deficiencies—that may be a more enlightened public policy.  By the way, it is one more consistent with the WHO position that we still have limited vaccine supply, and it would be far more appropriate and equitable to deploy that vaccine supply more broadly globally to protect the elders in particular throughout the world, rather than this focus on universal vaccination.  Now with a booster, a third booster, a third dose, there's been multiple statements by the WHO that they believe this is not ethical. Now, I had another interview today with a journalist podcaster who is from South Africa but living in France, and very aware of the French resistance that's developing now to vaccines with all those protests. Mr. Jekielek: To vaccine mandates, correct? Dr. Malone: In particular, yes. His point was that if you look at this through the eyes of emerging economies, this Western focus on universal vaccination of their populations and now a third vaccine for their populations and their unwillingness to share the technology is a form of imperialism and hegemony. The Western nations have access to this technology and these doses and they're not willing to share it with the rest of the world.  So we've got a series of things here where this kind of imbalance in distribution of these vaccines as a resource is creating or exacerbating concerns that exist widely in economically disadvantaged countries. There's just not a level playing field and we're all in this boat together with this disease. Yet we're not being equitable in distribution of the countermeasures that are available. Mr. Jekielek: This is fascinating, even as others that you're speaking with are asking, “Do we even need these at this point?” That's fascinating. Dr. Malone: Yes, I agree. So what does this mean? I don't know. What I sense is, again, we're in one of those moments where there is chaos. There's lack of structure and consensus about how to move forward. And my sense is, getting back to the U.S. government, we're in a position now where a lot of the core assumptions underlying the vaccine strategy have been called into question. We don't really know what's on the other side.  Then on top of that, it's becoming increasingly apparent that these repurposed drugs and other agents that could provide protection and mitigate death and disease, if they were deployed early in outpatient environments, access to those that are being actively suppressed. That's another one of those, “This doesn't make sense,” kind of problems. It is causing a lot of questioning about the motivations of those that are guiding public policy right now. The second part of this episode will be released on Saturday, Sept. 4, at 7 p.m. ET. Below is a list of references mentioned or related to the discussion in this episode:  “Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant” (Note: This is a preprint). “Fauci: Amount of virus in breakthrough delta cases ‘almost identical' to unvaccinated” — The Hill CDC: “Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021” “Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California” (Note: This is a preprint) “New delta variant studies show the pandemic is far from over” — ScienceNews “Read: Internal CDC document on breakthrough infections” — The Washington Post “New UCSF study: Vaccine-resistant viruses are driving ‘breakthrough' COVID infections” — The Mercury News “Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections” (Note: This is a preprint) “Having SARS-CoV-2 once confers much greater immunity than a vaccine—but vaccination remains vital” — Science “Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals” (Note: This is a preprint) “SARS-CoV-2 variants of concern and variants under investigation in England” — Public Health England “Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting” — The New England Journal of Medicine “Real-World Study Captures Risk of Myocarditis With Pfizer Vax” — MedPage Today CDC: “Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020—August 2021” “CDC: Covid-19 Vaccine Effectiveness Fell From 91% To 66% With Delta Variant“ — Forbes “SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans” — Nature CDC: “Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May-June 2021” “Causes and consequences of purifying selection on SARS-CoV-2” — Genome Biology and Evolution “The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus” — Journal of Travel Medicine “Mutation rate of COVID-19 virus is at least 50 percent higher than previously thought” — Phys.org “Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals” (Note: This is a preprint) Subscribe to the American Thought Leaders newsletter so you never miss an episode. You can also follow American Thought Leaders on Parler, Facebook, or YouTube. If you'd like to donate to support our work, you can do so here. Follow Epoch TV on Facebook and Twitter. 

COVID-19, NEJM vaccine safety paper, full-dose anticoagulation in COVID-19, AF and Exercise, and early results on EMPEROR-Preserved are the studies John Mandrola, MD, discusses in this week's podcast. https://www.medscape.com/twic 1 - COVID-19 - Heart Inflammation More Common After COVID Than After Vaccination https://www.medscape.com/viewarticle/957343 - Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting https://www.nejm.org/doi/full/10.1056/NEJMoa2110475 2 - Full dose AC in COVID-19 - Heparin's COVID-19 Benefit Greatest in Moderately Ill Patients https://www.medscape.com/viewarticle/956630 - Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2105911 - Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 https://www.nejm.org/doi/full/10.1056/NEJMoa2103417 3 - AF and Exercise - Aerobic Exercise Can Reduce AF Frequency, Severity: ACTIVE-AF https://www.medscape.com/viewarticle/957322 4 - EMPEROR AF - EMPEROR-Preserved: Empagliflozin Scores HFpEF Breakthrough https://www.medscape.com/viewarticle/957405 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

  Listen, Subscribe, Share the Show, Donate. Help us keep this train rollin! Notes & Links from Today's Show Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine https://pubmed.ncbi.nlm.nih.gov/33301246/ Pfizer BioNTech covid trial clinical protocols https://cdn.pfizer.com/pfizercom/2020-11/C4591001_Clinical_Protocol_Nov2020.pdf https://clinicaltrials.gov/ct2/show/NCT04368728 https://www.bitchute.com/video/4faYQMpfAS0t/ https://www.wsj.com/articles/more-kids-are-hospitalized-with-covid-19-and-doctors-fear-it-will-get-worse-11629624602 https://www.wsj.com/articles/in-los-angeles-this-covid-19-surge-is-different-from-earlier-outbreaks-11629558004 https://www.theepochtimes.com/bacon-may-disappear-in-california-as-pig-rules-take-effect_3929406.html https://www.theguardian.com/australia-news/2021/aug/20/sydney-anti-lockdown-protest-organiser-sentenced-to-eight-months-jail https://twitter.com/DamnedHistory/status/1429636796103725058 big shooting in britain blamed on incel movement a la a morning show out of england https://www.youtube.com/watch?v=BOq2KBjeJD4 https://www.reuters.com/world/asia-pacific/sydney-police-crack-down-planned-anti-lockdown-protest-2021-08-21/ https://www.theguardian.com/environment/2019/mar/09/american-food-giants-swallow-the-family-farms-iowa https://www.justice.gov/sites/default/files/atr/legacy/2014/06/13/AGW-00064-d.docx http://www.philfilms.utm.edu/1/kingcorn.htm https://jacobinmag.com/2021/01/big-ag-farm-subsidies-agriculture#:~:text=Turns%20out%202020%20was%20a,percent%20of%20net%20farm%20income https://www.msn.com/en-us/news/politics/anti-mask-states-could-face-civil-rights-investigations-education-secretary-says/ar-AANBwC0?ocid=msedgntp https://www.haaretz.com/us-news/hawaii-protests-over-covid-19-restrictions-afflicted-with-antisemitism-1.10140847 https://apnews.com/article/health-religion-education-coronavirus-pandemic-5abb8a7505515f8b3248f2f71914728b https://www.dailystar.co.uk/news/latest-news/baby-orangutan-kisses-pregnant-womans-24808909 https://www.the-sun.com/news/3515655/tattooed-covid-certificate-barcode-arm-tiktok-star-mcdonalds/   The Propaganda Report on Rokfin Part I: Inside The CFR's Fear-Based Pro Vaccine Propaganda Campaign PART II: Inside The CFR's Fear-Based Pro Vaccine Propaganda Campaign (2/2) The Propaganda Report on Patreon The Propaganda Report Store Support Our Sponsors! Donate... If you find value in the content we produce and want to help us keep this train rollin, drop us a donation via Paypal or become a Patreon. (links below) Every little bit helps. Thank you! And thank you to everyone who has and continues to support the show. It's your support that enables us to continue producing shows. Paypal Patreon Subscribe & Leave A 5-Star Review... Subscribe on iTunes Subscribe on Google Play Music Listen on Google Podcasts Listen on Tunein Listen on Stitcher Follow on Spotify Like and Follow us on Facebook Follow Monica on Twitter Follow Binkley on Twitter Subscribe to Binkley's Youtube Channel https://www.paypal.me/BradBinkley https://www.patreon.com/propagandareport https://twitter.com/freedomactradio https://twitter.com/MonicaPerezShow https://www.youtube.com/bradbinkley https://www.youtube.com/monicaperez  

La preoccupazione per la variante Delta ha portato molti stati ad accelerare i propri piani per una terza dose. Ma con tutti i paesi più sfruttati del mondo ancora da vaccinare il rischio di protrarre ulteriormente la pandemia è altissimoSono passati otto mesi dall'inizio della campagna vaccinale in tutto il mondo, e le aziende farmaceutiche iniziano a pubblicare i primi dati riguardo alla diminuzione di efficacia dei vaccini dopo qualche mese. I paesi più ricchi del mondo stanno uno alla volta facendo i conti con la necessità di una terza dose, prima ancora di aver finito la campagna vaccinale — e con gran parte del resto del mondo ancora a zero dosi.Questa settimana, il direttore generale dell'Oms Tedros Adhanom Ghebreyesus ha chiesto una sospensione della somministrazione delle terze dosi di vaccino, “almeno fino alla fine di settembre,” per permettere di vaccinare “almeno il 10%” (!) della popolazione di tutti i paesi. “Capisco le preoccupazioni di tutti i governi di proteggere i propri cittadini dalla variante Delta,” ha commentato Tedros, “ma non possiamo accettare che i paesi che hanno già usato quasi tutte le riserve di vaccini del mondo ne usino altri ancora.” La dichiarazione dell'OMS non è stata presa bene dagli Stati Uniti: l'addetta stampa della Casa bianca Jen Psaki ha detto che l'organizzazione sta “presentando una scelta falsa.” Psaki si è vantata del fatto che gli Stati Uniti finora hanno donato 110 milioni di dosi ai paesi che ne avevano bisogno — una quantità risibile rispetto a quanto necessario. Dopo otto mesi, la disuguaglianza vaccinale è ancora gravissima: mentre sia Stati Uniti che Unione europea corrono verso il 50% della popolazione vaccinata, ha ricevuto il vaccino solo l'1,8% della popolazione africana. Nei paesi classificati come ad alto reddito dalla Banca mondiale sono state distribuite 101 dosi ogni 100 persone; nei 29 paesi più sfruttati del mondo 1,7 dosi ogni 100 persone. Il dottor Bruce Aylward, uno dei consiglieri speciali di Tedros, ha ripetuto l'ovvio: l'emergere di nuove varianti dimostra che “non possiamo uscirne [dalla pandemia] finché tutto il mondo non è vaccinato.” Con una disparità vaccinale come quella attuale, l'obiettivo di vaccinare tutto il mondo, però, sembra impossibile.C'è del vero in quello che dice Psaki: gli Stati Uniti infatti, si sono ufficialmente schierati a favore della moratoria sui brevetti dei vaccini, insieme al resto del mondo. Su questo fronte, infatti, al WTO c'è l'Unione europea sostanzialmente isolata, nella strenua difesa del diritto di Pfizer / BioNTech, e delle altre grandi aziende farmaceutiche, di chiedere prezzi sempre più esorbitanti a dose, mentre il resto del mondo resta senza vaccino.Show notes Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine | medRxiv Should you get a third Covid vaccine dose? Booster shots explained Brusaferro (Iss): “Sì alla terza dose di vaccino per i più fragili. La crescita dei casi? Ora è più contenuta" | L'HuffPost Vaccini Lombardia, consegnate un milione di dosi in meno a luglio Le forniture frenano la corsa- Corriere.it Vaccino Covid, Ricciardi: "Terza dose andrà fatta, serve produrre di più" WHO Director-General's opening remarks at the media briefing on COVID-19 - 4 August 2021 WHO calls for moratorium on booster vaccine shots through September, citing global disparity - The Washington Post Coronavirus (COVID-19) Vaccinations - Statistics and Research - Our World in Data WHO calls for moratorium on COVID vaccine booster jabs | Coronavirus pandemic News | Al Jazeera Parliament calls for temporary COVID-19 vaccine patent waiver | News | European Parliament The patent waiver debate - PharmaTimes Magazine July 2021 EU seals deal with Novavax for up to 200 million COVID-19 vaccines | Reuters I profitti di Pfizer e l'impotenza della politica | il manifesto Let down by rich and failing the poor, global vaccine scheme to be shaken up | Reuters

輝瑞/BNT第三期臨床試驗追蹤了六個月後的結果。 每兩個月，保護力從96.2%降到90.1%降到83.7%但對重症的防護力都維持得非常好。 這要怎麼解讀？請聽這集！ Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1 Efficacy of Pfizer/BioNTech Covid vaccine slips to 84% after six months (statnews.com) https://www.statnews.com/2021/07/28/efficacy-of-pfizer-biontech-covid-vaccine-slips-to-84-after-six-months-data-show/ 給長輩的AZ疫苗懶人包 https://linshibi.com/?p=39590 高端 聯亞 國產疫苗懶人包 第二期結束就緊急授權可行嗎？ https://linshibi.com/?p=39547 新冠快篩懶人包 普篩 抗體快篩 抗原快篩 https://linshibi.com/?p=36564 新冠肺炎疫情下的防疫須知 常見問題解答FAQ https://linshibi.com/?p=35408 新冠疫苗常見問題懶人包 https://linshibi.com/?p=38945 林氏璧醫師的電子名片 https://lit.link/linshibi 歡迎贊助我喝咖啡 https://pay.firstory.me/user/linshibi Powered by Firstory Hosting

This week, we review data on the short-term safety of the COVID-19 vaccine in patients with cancer receiving immunotherapy. We'll also discuss a study of the monoclonal antibody tislelizumab plus chemotherapy as first-line treatment for patients with advanced squamous non–small cell lung cancer.Coverage of stories discussed this week on ascopost.com:Short-Term Safety of the BNT162b2 mRNA COVID-19 Vaccine in Patients Receiving ImmunotherapyFirst-Line Tislelizumab Plus Chemotherapy vs Chemotherapy Alone in Advanced Squamous NSCLCTo listen to more podcasts from ASCO, visit asco.org/podcasts.

In this journal club episode, Dr. Matt Fox and Dr. Hailey Banack discuss a paper recently published in the New England Journal of Medicine by Dagan et al. on the Pfizer COVID-19 vaccine. Listen in for a real-world example of the concept of emulating a target trial and a discussion of how an epidemiologic study can be described as truly beautiful. Reference: Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021 Feb 24:NEJMoa2101765. doi: 10.1056/NEJMoa2101765. Epub ahead of print. PMID: 33626250; PMCID: PMC7944975.

The unbelievable happened in 2020 - a vaccine was developed with high efficacy within 12 months for a novel virus! In December two vaccines for the prevention of the SARS-CoV-2 virus were approved through Emergency Use Authorization in the US. Is it time to get a shot? This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today! Reference: Polack F, Thomas S, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. NEJM. Dec 10, 2020. DOI: 10.1056/NEJM2034577 Baden L, El Sahly H, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. NEJM. Dec 30, 2020. DOI: 10.1056/NEHMoa2035389 ACIP Recommendations: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html  See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

The unbelievable happened in 2020 - a vaccine was developed with high efficacy within 12 months for a novel virus! In December two vaccines for the prevention of the SARS-CoV-2 virus were approved through Emergency Use Authorization in the US. Is it time to get a shot?This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!Reference: Polack F, Thomas S, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. NEJM. Dec 10, 2020. DOI: 10.1056/NEJM2034577Baden L, El Sahly H, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. NEJM. Dec 30, 2020. DOI: 10.1056/NEHMoa2035389ACIP Recommendations: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html See omnystudio.com/listener for privacy information.

The unbelievable happened in 2020 - a vaccine was developed with high efficacy within 12 months for a novel virus! In December two vaccines for the prevention of the SARS-CoV-2 virus were approved through Emergency Use Authorization in the US. Is it time to get a shot? This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today! Reference: Polack F, Thomas S, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. NEJM. Dec 10, 2020. DOI: 10.1056/NEJM2034577 Baden L, El Sahly H, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. NEJM. Dec 30, 2020. DOI: 10.1056/NEHMoa2035389 ACIP Recommendations: https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html  See omnystudio.com/listener for privacy information.

Au moment d'enregistrer cet épisode, le 8 janvier 2021, la pandémie a déjà fait plus de 8500 morts au Québec. Heureusement, la vaccination a commencé le 14 décembre dernier. Dans ce spécial COVID-19, nous discutons de l'efficacité et de l'innocuité des vaccins, ainsi que des éléments associés à leur distribution et leur préparation. Pour nous en parler, nous recevons Rachel Rouleau, chef-adjointe et pharmacienne au CIUSSS de la Capitale-Nationale, l'un des premiers établissements responsables de cette distribution. Références Agence de la santé publique du Canada. Plan de vaccination du Canada contre la COVID-19 : sauver des vies et protéger les moyens de subsistance. Décembre 2020. https://www.canada.ca/fr/sante-publique/services/maladies/2019-nouveau-coronavirus/reponse-canada/plan-vaccination-canada-contre-covid-19.html Aschwanden C. The false promise of herd immunity for COVID-19. Nature. 587 (2020) : 26-28. https://www.nature.com/articles/d41586-020-02948-4 FP Polack. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. December 31, 2020. N Engl J Med 2020; 383:2603-2615. DOI: 10.1056/NEJMoa2034577 https://www.nejm.org/doi/full/10.1056/NEJMoa2034577 Institut national de santé publique du Québec. Caractéristiques des vaccins candidats contre la COVID-19 et enjeux relatifs à leur utilisation au Québec. https://www.inspq.qc.ca/sites/default/files/publications/3069-caracteristiques-vaccins-candidats-enjeux-covid19.pdf LR Baden et coll. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. December 20. 2020. DOI : 10.1056/NEJMoa2035389 https://www.nejm.org/doi/full/10.1056/NEJMoa2035389 Ministère de la Santé et des Services Sociaux du Québec. Vaccination contre la COVID-19 (professionnels de la santé). 2020. https://msss.gouv.qc.ca/professionnels/covid-19/vaccination-contre-la-covid-19/ Ministère de la Santé et des services sociaux du Québec. Vaccins à ARN messager contre la COVID-19. 2020. https://msss.gouv.qc.ca/professionnels/vaccination/piq-vaccins/covid-19-vaccin-a-arn-messager-contre-la-covid-19/ Barnabas RV. A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose. Ann Intern Med 2021 Jan5. doi:10.7326/M20-8060. https://www.acpjournals.org/doi/full/10.7326/M20-8060

本來打算落晒啲reference，但係個browser死咗之後開返又閂咗....由佢喇，反你哋都唔會睇...... Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (Pfizer/BioNTech; https://www.nejm.org/doi/full/10.1056/NEJMoa2034577) Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults (Moderna; https://www.nejm.org/doi/full/10.1056/NEJMoa2028436) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation (S protein structure; https://science.sciencemag.org/content/367/6483/1260) Covid-19: What have we learnt about the new variant in the UK? (Link to the information on UK variant; https://www.bmj.com/content/371/bmj.m4944) expert reaction to South African variant of SARS-CoV-2 (South Africa variant; https://www.sciencemediacentre.org/expert-reaction-to-south-african-variant-of-sars-cov-2-as-mentioned-by-matt-hancock-at-the-downing-street-press-briefing/) --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Continuing the powerful conversation with Dr. Eric Payne, this second part dives even further into the challenges facing healthcare professionals in the wake of the COVID pandemic. Dr. Payne sheds light on the rising fear among physicians who hesitate to speak out against mainstream medical narratives due to censorship and professional repercussions. We examine the growing concerns about vaccine safety, particularly in relation to neurological injuries, and highlight cases of doctors facing backlash for raising these issues. The episode also speaks to the profound effects of masking mandates on children's development and emphasizes the urgent need for critical thinking and open dialogue in both the medical community and society. Tune in for this thought-provoking discussion that encourages us all to engage in truth-seeking discussions that build a better future. Dr. Eric Payne is a neurologist and clinical researcher specializing in pediatric neurology, epilepsy, neuroinflammation, and neurocritical care. He previously worked as an epileptologist and pediatric neurologist at Mayo Clinic (2014-2020) and at Alberta Children's Hospital (2020-2023).  He completed medical school and residency at the University of Calgary, and fellowship training in pediatric neurocritical care and epilepsy at the Hospital for Sick Children in Toronto. He obtained a Master of Public Health from Harvard University and is board certified in Neurology (FRCPC) and Clinical Electroencephalography (CSCN).  —Listen to Part One: Reclaiming Integrity in Medicine with Top Pediatric Neurologist Dr. Eric Payne: https://markgroves.com/episode/reclaiming-integrity-in-medicine-with-top-neurologist-dr-eric-payne/  References from the Episode: —Dr. Eric Payne's Letter: https://smartcdn.gprod.postmedia.digital/calgaryherald/wp-content/uploads/2021/09/Sep-15-FINAL-PAYNE-CPSA-letter.pdf  —Full List of Dr. Payne's References From His Letter:  https://static.showit.co/file/rXKal_TV4PXpWv42QajRqA/237093/sep-15-final-payne-cpsa-letter-references.pdf  —Still Face Experiment: Dr. Edward Tronick: https://youtu.be/vmE3NfB_HhE?si=QivHWP9_jREexK3s&t=34 —Cochrane Report on Face Masks: https://www.cochrane.org/CD006207/ARI_do-physical-measures-such-hand-washing-or-wearing-masks-stop-or-slow-down-spread-respiratory-viruses  —Updated Definitions of Immunity and Vaccine: https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm  —Primary Trials: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine: https://www.nejm.org/doi/full/10.1056/NEJMoa2034577  Resources: —Ready to transform your relationships? Download The Relationship Toolkit for free and learn the 5 essential skills to thrive in love and life! https://go.markgroves.com/relationship-toolkit-podcast  —Ready to stop chasing emotionally unavailable people? Download your free guide to break the cycle and call in the relationship you crave: https://go.markgroves.com/unavailable-people-opt-in-podcast  —Learn the connection between Attachment Styles, how it affects the Nervous System, AND how you can heal it: .https://go.markgroves.com/nervous-system-opt-in-podcast If you want to dive deeper into Mark's content, search through every episode, find specific topics we've covered, and ask him questions, go to his Dexa page: https://dexa.ai/markgroves Contact us at podcast@markgroves.com for sponsor product support, questions, comments, or just to say hello!

Dr. Eric Payne, an esteemed pediatric neurologist with a background in public health, offers an insightful and thought-provoking critique of the public health responses to COVID-19. In this part one of a two-part conversation, he discusses how fear, media narratives, and public health policies have deeply impacted society, particularly children. Dr. Payne explores the unintended consequences of lockdowns, school closures, and mask mandates, highlighting the emotional, social, and ethical dilemmas they created. His reflections challenge mainstream perspectives, advocating for more open dialogue around these interventions, especially in the face of widespread public mistrust. This conversation invites us all to reconsider the long-term impacts of pandemic policies and opens up space for healing and understanding across diverse viewpoints. Dr. Eric Payne is a neurologist and clinical researcher specializing in pediatric neurology, epilepsy, neuroinflammation, and neurocritical care. He previously worked as an epileptologist and pediatric neurologist at Mayo Clinic (2014-2020) and at Alberta Children's Hospital (2020-2023).  He completed medical school and residency at the University of Calgary, and fellowship training in pediatric neurocritical care and epilepsy at the Hospital for Sick Children in Toronto. He obtained a Master of Public Health from Harvard University and is board certified in Neurology (FRCPC) and Clinical Electroencephalography (CSCN).  —Listen to Part Two: Healthcare, Ethics, and the Pandemic: Dr. Eric Payne's Call for Truth and Integrity: https://markgroves.com/episode/healthcare-ethics-and-the-pandemic-dr-eric-paynes-call-for-truth-and-integrity/ References from the Episode: —Dr. Eric Payne's Letter: https://smartcdn.gprod.postmedia.digital/calgaryherald/wp-content/uploads/2021/09/Sep-15-FINAL-PAYNE-CPSA-letter.pdf  —TikTok Tics: https://pmc.ncbi.nlm.nih.gov/articles/PMC8564823/  —Updated Definitions of Immunity and Vaccine: https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm  —Full List of Dr. Payne's References From His Letter:  https://static.showit.co/file/rXKal_TV4PXpWv42QajRqA/237093/sep-15-final-payne-cpsa-letter-references.pdf  —Cochrane Report on Face Masks: https://www.cochrane.org/CD006207/ARI_do-physical-measures-such-hand-washing-or-wearing-masks-stop-or-slow-down-spread-respiratory-viruses  —Primary Trials: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine: https://www.nejm.org/doi/full/10.1056/NEJMoa2034577  Resources: —Ready to transform your relationships? Download The Relationship Toolkit for free and learn the 5 essential skills to thrive in love and life! https://go.markgroves.com/relationship-toolkit-podcast  —Ready to stop chasing emotionally unavailable people? Download your free guide to break the cycle and call in the relationship you crave: https://go.markgroves.com/unavailable-people-opt-in-podcast  —Learn the connection between Attachment Styles, how it affects the Nervous System, AND how you can heal it: .https://go.markgroves.com/nervous-system-opt-in-podcast If you want to dive deeper into Mark's content, search through every episode, find specific topics we've covered, and ask him questions, go to his Dexa page: https://dexa.ai/markgroves This episode is sponsored by Cozy Earth: Use code MARK for 40% off sitewide at http://www.cozyearth.com Contact us at podcast@markgroves.com for sponsor product support, questions, comments, or just to say hello!